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ABSTRACT OF THE DISSERTATION

The Effects of Dietary N-3 Polyunsaturated Fat from Plant versus Marine Sources
on Biochemical Markers of Bone Turnover in Healthy Adults
By
Lan Nguyen
Doctor of Public Health in Nutrition
Loma Linda University, Loma Linda CA, 2009
Sujatha Rajaram, Chairman

Objective: To investigate the effects of dietary n-3 polyunsaturated fat from plant versus
marine sources on biochemical markers of bone turnover.
Design: Both studies were controlled, single blind, randomized trials using Latin-square
crossover designs.
Subjects/Methods: Twenty-five (12 females and 13 males) and 24 (9 females and 15
males) healthy participants completed the Fish-Walnut Study and the Omega-3 Study,
respectively. The Fish-Walnut Study included three diets: [1] control, [2] ALA-rich diet
(1.5 oz of walnuts/day, 6 times/week), and [3] EPA/DHA-rich diet (8 oz of
salmon/week). The Omega-3 Study included four diets: [1] control, [2] ALA-rich diet
(42-49 g flaxseed oil/wk; lOg walnuts, 3 times/week), [3] EPA/DHA-rich diet (1.40/5.04
g EPA/DHA from microalgae oil/wk), and [4] combination diet (including both ALA and
EPA/DHA diets). After a 1-week run-in phase, participants were randomly assigned to a
diet for 4 weeks each for the Fish-Walnut Study and 8 weeks each for the Omega-3
m

Study. Biochemical markers of bone turnover [c-telopeptide (CTX); procollagen Type I
N-terminal propeptide (PINT); and osteocalcin (OC)] were analyzed in serum at the end
of each diet period in both studies.
Results: There were no significant changes in serum CTX, P1NP, and OC among the
three diets (p > 0.05) in both studies. In the Fish-Walnut Study, there was a significant
negative association between P1NP levels and age (p = 0.005). In the Omega-3 Study,
there was a significant negative association between age and CTX (p<0.0001), P1NP
(p=0.0006), and OC (p=0.002). There was also a negative association between CTX with
RBC LA and ALA and a positive correlation between CTX and RBC DHA for the
Omega-3 Study (p<0.05).
Conclusion: Our findings suggest that both an ALA-rich diet and an EPA/DHA-rich diet
did not alter biochemical markers of bone resorption (CTX) and formation (P1NP and
OC) in healthy adults in this study design.
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CHAPTER 1
INTRODUCTION

A. Statement of the Problem
In the United States, the estimated healthcare costs (hospital utilization, Medicare,
and lost productivity) for the management and treatment of bone joint diseases is $15
billon dollars per year (Gueldner et ah, 2008). The National Osteoporosis Foundation
approximates that 44 million Americans are at risk or already afflicted with osteoporosis,
a condition of reduced bone mass that is prevalent among postmenopausal females (Haas
& Moore, 2007). While the numbers are staggering, medical experts believe that
osteoporosis and other bone-related diseases can be delayed or prevented with early
detection and proper treatment (Love, 2003). Due to the high morbidity and mortality
rates associated with bone joint diseases, it is imperative to identify alternative
therapeutic treatments for reducing the incidence of metabolic bone diseases.
Conventional synthetic medications contain numerous side effects and the majority of
patients cannot afford or do not have access to adequate healthcare (Laroche, 2008).
Recent scientific evidence suggests that specific polyunsaturated fats, especially
dietary intake of n-3 polyunsaturated fatty acids (n-3 PUFA), exert protective effects on
bone health (Grid et ah, 2007; Shen et ah, 2006; Watkins et ah, 2006). Human studies
show that n-3 PUFA regulate osteoblast and osteoclast production, cells which play a
significant biological role in bone formation and resorption (Baggio et al., 2005). alinolenic acid (ALA, 18:3 n-3) is a parent compound for long-chain n-3 PUFA
metabolism and yields eicosapentaenoic acid (EPA, 20:5 n-3) and docosahexaenoic acid
1

(DHA, 22:6 n-3) through a series of elongase and desaturase reactions. EPA and DHA
are precursors to a variety of metabolites which regulate the fatty acid composition of
skeletal compartments (Watkins et ah, 2001). N-3 PUFA especially ALA is essential for
human growth and development and must be obtained through the diet. The majority of
ALA can be obtained from dietary sources of plant products, while EPA and DHA are
predominately consumed through marine sources (Poulsen et ah, 2007).
While there is scientific agreement concerning the cardioprotective effects of n-3
PUFAs, relatively few human studies have been conducted to date on the potential
protective effects of n-3 PUFAs on bone health (Watkins et ah, 2001). Grid et al. (2007)
conducted one of the first randomized, crossover feeding trials which assessed the effects
of an ALA-rich plant-based diet on bone turnover in humans. They showed that the
ALA-rich diet significantly reduced collagen-based bone resorption marker, n-telopeptide
(NTX). However, no significant changes were observed in bone-specific alkaline
phosphatase (BSAP) levels, an accepted marker of bone formation secreted by
osteoblasts. These mixed results indicate that further studies are needed in order to
assess the potential protective effects of dietary n-3 PUFAs, especially ALA and
EPA/DHA, on skeletal health. Additionally, little is known about the exact mechanism
of action by which these n-3 PUFAs may affect bone remodeling.
B. Purpose of the Study
The primary purpose of our study was to determine the effects of plant (ALA
rich) versus marine (EPA/DHA rich) sources of n-3 PUFAs on biomarkers of bone
turnover in healthy adults.
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C. Objectives
The primary objectives were to investigate the effects of dietary n-3 PUFAs from
plant versus marine sources on biochemical markers of bone turnover in healthy adults.
Blood samples from two carefully monitored feeding studies will be used to compare
ALA rich diets (walnuts, flaxseed oil) to EPA/DHA rich diets (salmon, micro algae oil)
in healthy males and females with respect to biomarkers of bone remodeling.
The following biochemical markers of bone turnover will be used: serum Ctelopeptide (CTX; bone resorption marker), osteocalcin (OC; bone formation marker),
and procollagen type I N-terminal propeptide (PINP; bone formation marker).
D. Research Questions
1) Will consumption of n-3 rich plant and/or marine-based diets influence bone
formation, through biomarkers Procollagen type 1 N-terminal propeptide (PINP)
and Osteocalcin (OC), in healthy adults?
2) Will consumption of n-3 rich plant and/or marine-based diets influence bone
resorption, through biomarker C-telopeptide (CTX), in healthy adults?
3) Will n-3 rich plant versus marine-based diets exert biologically equivalent effects
on bone maintenance in healthy adults?
E. Significance to Nutrition
Due to the high morbidity and mortality rates associated with skeletal fractures,
preventive strategies are essential in helping to reduce the onset and progression of bone
joint diseases. Enhanced dietary n-3 PUFA intake may be one preventive treatment
which could potentially delay the incidence of accelerated bone resorption by a few years
or more (Salari et ah, 2008). The impact this would have towards reducing healthcare
3

costs and lost productivity would be tremendous, including improving the quality of life
for those afflicted.
There is currently limited research and information pertaining to the specific
protective effects either ALA or EPA/DHA has on skeletal health and the biological
impact certain proteins, hormones, and minerals have in influencing bone maintenance.
The American Heart Association and the Food and Drug Administration currently
recommend two servings of fatty fish/wk and 1.5 oz of walnuts/d, respectively, in order
to optimize cardioprotective effects (Lichtenstein et ah, 2006; Tarantino, 2004). There
are no such dietary recommendations for n-3 PUFAs in preventing bone loss even though
epidemiological studies have indicated an association between increased n-3 PUFA
intake and improved skeletal outcomes (Salari et al., 2008; Poulsen et al., 2007). In order
to understand if there is indeed a cause and effect relationship between n-3 PUFAs and
bone health, we conducted the following research using previously obtained biological
samples from the Fish-Walnut and Omega-3 Studies. Ascertaining the role of these
bioactive nutrients in bone health is especially important to vegetarian and vegan
populations who do not have a direct source of dietary EPA/DHA.
In addition, these carefully monitored feeding studies will provide valuable data
on dose response effects of ALA and EPA/DHA intake on bone turnover. Both studies
have used varying amounts of n-3 PUFAs in order to demonstrate the probable amounts
necessary in which to observe positive effects on bone turnover. The relative safety and
accessibility of dietary n-3 PUFAs increases the need for research in this area.
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CHAPTER 2
LITERATURE REVIEW

A. Introduction
1. Background on Osteoporosis
Osteoporosis is the most widespread metabolic bone disorder, affecting
approximately 200 million patients worldwide. In the U.S., there are over 10 million
cases reported and an estimated 34 million individuals have low bone mineral density
(Gardner et al., 2006). This prevalent disease is characterized by low bone mass and
degradation of bone tissue, which leads to bone fragility and susceptibility to fractures
(Fernandes et al., 2003). Annually, there are over 1.5 million fracture cases in the U.S.
alone. The most common osteoporotic-related fractures are spinal but hip fractures result
in the highest economic losses and mortality rates (Report of the Surgeon General, 2004).
Osteoporosis can be categorized under primary or secondary osteoporosis.
Primary osteoporosis occurs as a result of age-related bone loss and is not caused by
other diseases or medication use. While primary osteoporosis does occur in men, this
disease is two or three times more prevalent in women (Gueldner et al., 2008).
Secondary osteoporosis occurs due to affliction with another disease or medication
intake. Diseases which contribute to secondary osteoporosis include genetic disorders
such as cystic fibrosis and hemochromatosis, endocrine disorders including Type I
Diabetes and hyperthyroidism, and gastrointestinal disorders such as celiac disease and
inflammatory bowel disease (Bilezikian et al., 2002).

5

Osteoporosis is diagnosed with a T-score below -2.5, which is the standard
deviation below the mean reference value for a healthy population at peak bone mass.
Risk factors include advanced age, Caucasian/Asian ethnic background, family history,
being female, low body mass index, inactive lifestyle, and malnutrition (Javaid & Holt,
2008). Currently, there are numerous problems associated with the treatment of
osteoporosis, including lack of information about the long-term efficacy of synthetic
medications, combined treatment therapies, and safe doses for specific populations
(Larcohe, 2008). Clinicians agree that certain types of osteoporosis can be prevented, so
it is imperative to identify safe, alternative treatments for reducing the incidence of
osteoporosis and other bone-related diseases.
2. Cellular Bone Biology
At the cellular level, bone consists of three major cell types: osteoblasts,
osteocytes, and osteoclasts. These three cell types interact with numerous systemic
hormones, proteins, and minerals in order to continually eliminate worn bone in exchange
for new bone in a coupled process called bone remodeling (Gueldner et al., 2008).
Osteoblasts are mononucleated cells which are produced by mesenchymal stem cells
(Figure 1). These anabolic, bone-forming cells are responsible for producing Type I
collagen and mineralizing the bone matrix (Bilezikian et al., 2002).
Osteocytes are mature osteoblasts which reside within the bone matrix and its
function includes sensing mechanical strain and promoting signaling pathways. As the
most frequent cell type in bone, osteocytes can also carry out its mechanosensory
function on bone surfaces, which then become known as bone lining cells (Gueldner et
al., 2008).
6

Osteoclasts are multinucleated cells which are produced from haematopoetic stem
cells (Figure 1). In contrast to osteoblasts, osteoclasts have a catabolic function whereby
these cells remove old and damaged bone through releasing hydrolytic enzymes through
the ruffled border area of its plasma membrane. Differentiation and maturation of
osteoclasts actually depend on proteins generated or secreted by osteoblasts (Tanaka et
ah, 2005).
The normal process of bone remodeling involves the coupled reactions of both
osteoclasts and osteoblasts in order to regulate bone resorption and bone formation.
However, chronic metabolic bone diseases such as osteoporosis occur when these
reactions become uncoupled and bone resorption surpasses bone formation (Salari et al.,
2008)

Figure 1. Osteoblastic/Osteoclastic Cell Lineage

3. Bone Resorption Markers
During bone remodeling, there is a bone resorption phase that must take
place before bone formation can occur. Osteoclastic bone resorption involves two steps:
7

demineralization and digestion of protein. In the process of demineralization, osteoclasts
release hydrogen ions from its ruffled border plasma membrane onto a localized area of
bone in order to acidify and dissolve the skeletal matrix (Bilezikian et ah, 2002). In the
second step, hydrolytic enzymes, predominately from the cathepsin family, are released
to degrade the organic parts of the matrix. The byproducts of this enzymatic degradation
are collagen crosslinks or peptide fragments, N- telopeptide (NTX) and C-telopeptide
(CTX) (Lark & James, 2002). These fragments can enter the circulation and can be
measured in serum and urine. NTX and CTX are valuable indicators of osteoclastic bone
resorption (Rosen et al., 2000).
4. Bone Formation Markers
After completion of the bone resorption phase, bone formation can begin
whereby Type 1 collagen must be produced to provide skeletal strength and support.
Type I collagen is the most abundant type of collagen found in bone and occupies 95% of
the organic matrix (Bilezikian et al., 2002). Many of the most common bone formation
markers, such as procollagen type I N-terminal propeptide (PINT) and procollagen type I
C-terminal propeptide (PICP), are a result of Type 1 collagen synthesis and maturation.
The procollagen peptide is formed and arranged into a triple helix structure inside
osteoblasts cells. The procollagen precursor is then secreted into the matrix where it is
enzymatically cleaved at the N- and C-terminals, yielding PINP and PICP, which are
released into the blood. PINP and PICP can be used as bone markers in order to monitor
Type 1 collagen synthesis, and consequently, bone formation (Eastell & Hannon, 2008)
Osteocalcin is a protein produced by a variety of cells, including osteoblasts.
Osteocalcin is secreted in the skeletal matrix for osteoblast maturation and to recruit
8

osteoclasts. Serum levels of osteocalcin are specific and sensitive indicators of osteoblast
activity, which make them an appropriate marker for bone formation (Gueldner et ah,
2008; De Vemejoul, 1998).
5. Dietary Factors Influencing Bone Maintenance
Epidemiological research shows that various dietary habits and lifestyle
factors influence bone maintenance. Smoking has long been associated with negative
health outcomes, including increased susceptibility to fractures and bone loss. A high
level of cadmium, a heavy metal present in tobacco, is believed to play a significant role
in inducing bone resorption (Syversen et al, 1999). Excessive alcohol consumption has
been shown to influence bone maintenance due to malnutrition and malabsorption of
nutrients. Research indicates that heavy alcohol intake increases fracture risk and can
cause secondary osteoporosis (Kanis et al., 2005). Medications, such as corticosteroids,
reduce calcium absorption in the intestines and increase calcium excretion from the
kidneys. Even minimal doses of oral glucocorticoids (2.5-7.5 mg/d of Prednisone) have
been linked to increased fracture risk (Van Staa et al., 2002). Low and high protein
intake can adversely affect skeletal health. Studies indicate that patients with low protein
intake (less than 0.8 g protein/kg in adults) have reduced lean muscle mass and lower
bone mineral density (Kerstetter et al., 2003). Patients on high protein diets have been
observed to have increased levels of urinary calcium excretion (Tucker, 2003).
Additionally, specific vitamins directly affect bone structure, making adequate dietary
intake essential. Vitamin C is required for the formation of collagen, fibrous proteins,
and cartilage (Sahni et al., 2008). Vitamin K is essential for carboxylation reactions
which activate bone-forming proteins, such as osteocalcin, and enable this protein to
9

function properly (Cheung et al., 2008). Vitamin D maintains blood calcium levels and
bone status. Calcium is the most abundant mineral in bone and is an essential cofactor
for collagen synthesis. Adequate amounts of this mineral can enhance or reduce peak
bone mass, especially during early puberty (Eastell & Lambert, 2002).
Recent scientific evidence suggests that specific polyunsaturated fats, especially
dietary intake of ALA and EPA/DHA, exert protective effects on bone health (Griel et
al., 2007; Shen et al., 2006; Watkins, Yong, & Seifert, 2006). The following section will
investigate why these n-3 PUFAs may play a vital role in bone maintenance.
B. N-3 Polyunsaturated Fatty Acids
1. Background on N-3 Polyunsaturated Fatty Acids
N-3 polyunsaturated fatty acids (PUFAs) are long chain fatty acids that
contain at least 18 carbons and a minimum of 3 double bonds. N-3 PUFAs are essential
for humans because we lack enzymes necessary to insert double bonds closer to the
methyl end of these long-chain fats. Flowever, plant and certain marine fish are able to
synthesize n-3 PUFAs from other short chain fatty acids, which make these plant and
marine sources critical for human health (Poulsen et al., 2007). While the adequate
intake of n-3 PUFAs for men and women are 1.6 and 1.1 g/d, respectively, research
shows that most Americans consume less than the recommended values. In Europe,
Australia, and North America, typical n-3 PUFA intake ranges between 0.6-1.7 and 0.51.4 g/d for men and women, respectively (Burdge & Calder, 2005).
Physiological functions of n-3 PUFAs and their derivatives include incorporation
in plant and animal cell membranes as structural phospholipids and precursors of
eicosanoids (Albertazzi & Coupland, 2002). N-3 PUFAs are precursors to metabolites
10

which regulate the fatty acid composition of skeletal cells (Watkins et ah, 2001). N-3
PUFAs contain more than one point of unsaturation which enhances cell membrane
fluidity. When cell membranes are more fluid, this increases the number and potency of
cell surface receptors and enzyme function which are critical for optimal interactions with
bone-generating growth factors and hormones (Poulsen et ah, 2007). Additionally, n-3
PUFAs can produce eicosanoids, which include prostaglandins, thromboxanes, and
leukotrienes. Research indicates these eicosanoids have anti-thrombotic, anti
inflammatory, and vasodilatory properties which can help reduce the onset and
progression of chronic diseases such as heart disease, diabetes, arthritis, autoimmune
disorders, and cancer (Covington, 2004). Emerging research indicate that n-3 PUFAs
exert protective effects on skeletal health as well. Populations known to consume high
amounts of n-3 PUFA-rich fish, such as the Japanese and Greenland Eskimos, have lower
rates of osteoporosis (Kruger & Scholium, 2005). The major n-3 PUFAs believed to play
a central role in regulating bone maintenance includes ALA and EPA/DHA.
2. Background on a-linolenic Acid (ALA)
a-linolenic acid (ALA) is the parent compound in the metabolism of n-3
long chain PUFAs. The concentration of ALA in mammalian cell membranes is
extremely low and makes up less than 0.5% of total fatty acids in plasma phospholipids
(Burdge & Calder, 2005). The specific functional and protective effects of ALA are
contributed to its conversion to longer chain n-3 PUFAs, EPA and DHA. However, the
conversion of ALA to EPA/DHA is minimal in humans due to competition for
desaturase/elongase enzymes, advanced age, and other metabolic disorders (Albertazzi et
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al., 2002). Additionally, a study by Burdge showed that conversion of ALA to
EPA/DHA was significantly lower in men than that of women (2006).
While conversion of ALA to EPA/DHA is low, human trials do show that it is a
normal physiological occurrence. In a 12-wk clinical trial, 2.4 and 3.6 g of flaxseed oil
supplementation per day significantly increased erythrocyte EPA and DHA levels
(Barcelo-Coblijn et al., 2008). Results suggest that ALA conversion can be obtained in
dosage amounts safe for supplementation by the general public. Since ALA is present in
plant chloroplasts, the best sources include seeds, nuts, plant oils, green leafy vegetables,
and beans (Table 1) (USDA Nutrient Data Laboratory, 2008).
Table 1. Dietary Sources of a-linolenic acid (ALA)
Source
Flaxseed Oil
Flaxseed, Ground
Walnuts
Canola Oil
Tofu

ALA (g)
8.0
3.8
2.6
1.3
0.7

Amount
1 tablespoon
1 tablespoon
1 oz
1 tablespoon
4.5 oz

The dietary sources of ALA utilized in our research were walnuts and flaxseed
and these sources are further discussed below.
a. Importance of Walnuts Walnuts are a member of the Juglandaceae
family {Juglans) and are cultivated around the world, from southeast Europe, Japan,
Canada, to California. Walnuts are a rich source of fiber, magnesium, potassium,
arginine, Vitamin E, and unsaturated fatty acids (Table 2) (USDA Nutrient Data
Laboratory, 2008). These nuts are high in essential polyunsaturated fatty acids, omega-6
(n-6) and n-3 PUFAs, with n-6: n-3 ratio of 4:1 (Almario et al., 2001). Of all the tree
nuts, walnuts have one of the highest levels of antioxidants (AOX) at more than 20 mmol
12

AOX per 100 g (Blomhoff et al., 2006). These nuts are especially high in ALA at
approximately 2.6 g of ALA/oz.
Epidemiological studies show that routine walnut consumption (5 oz nuts/wk) can
help reduce coronary heart disease by 50%, even after controlling for age, body mass
index, physical activity, and herbal supplementation (Ros et al., 2004). Since walnuts are
nutrient dense, the therapeutic effects of these nuts could possibly extend beyond
cardioprotective effects to positively influence skeletal health as well.
b. Importance ofFlaxseed and Flaxseed Oil Flaxseed or linseed is a
member of the Linum family (Linum usitatissimum) and is native to regions ranging from
the eastern Mediterranean to India. Flaxseed and its derivative flaxseed oil are the
richest sources of ALA, the biologic precursor to EPA and DHA (Daun et al., 2003).
Table 2. Nutritional Composition of Walnuts
Serving Size: 100 g (3.5 oz)
13.7 g
2.61 g
6.7 g
65.2 g
15.2 g
0.34 mg
0.15 mg
1.13 mg
0.57 mg
0.54 mg
98 jig
1.3 mg
98 mg
2.9 mg
158 mg
346 mg
441 mg
3.1 mg
3.4 mg
4.9 mg

Nutrients
Carbohydrates
Sugars
Dietary fiber
Fat
Protein
Thiamin
Riboflavin
Niacin
Pantothenic acid
Pyridoxine
Folate
Vitamin C
Calcium
Iron
Magnesium
Phosphorus
Potassium
Zinc
Manganese
Selenium
Source: USDA Nutrient Database
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In flaxseed oil, the plant lignan and soluble fiber components have been filtered
through, leaving only the ALA-rich portion. Ground flaxseed and flaxseed oil contain
approximately 3.8 and 8.0 g of ALA per tablespoon, respectively. The fatty acid
composition of flaxseed oil is approximately 15% n-6 and 56% ALA, for an n-6: n-3 ratio
of 1:4 (Cohen et al., 2005). Flaxseed and flaxseed oil are rich sources of B Vitamins
(thiamin, riboflavin, pantothenic acid and pyridoxine), iron, magnesium, and phosphorus
(Table 3) (USDA Nutrient Data Laboratory, 2008).
Current research shows that flaxseed oil may help prevent cardiovascular disease
(Bloedon & Szapary, 2004) and breast cancer (Thompson, 2003). It is believed the
therapeutic effects of flaxseed oil may extend to skeletal health as well. Weiler et al.
(2007) showed that rats fed a flaxseed oil diet (7% by weight) for 12 wks had increased
bone mineral content. However, Cohen et al. (2005) showed that growing mice fed 10%
flaxseed oil diets for 9 wks had no significant changes in bone mineral content. These
conflicting results indicate further research is necessary in order to assess what role
flaxseed and flaxseed oil might have in regulating bone turnover, especially as a
therapeutic treatment towards delaying the onset of metabolic bone disease.
Table 3. Nutritional Composition of Flaxseed
Nutrients
Carbohydrates
Sugars
Dietary fiber
Fat
Protein
Thiamin
Riboflavin
Niacin
Pantothenic acid
Pyridoxine
Folate

Serving size: 100 g (3.5 oz)
28.9 g
1.6 g
27.3 g
42.2 g
18.3 g
1.64 mg
0.16 mg
3.1 mg
0.99 mg
0.47 mg
0 Fg
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Table 3 (continued). Nutritional Composition of Flaxseed
Nutrients
Vitamin C
Calcium
Iron
Magnesium
Phosphorus
Potassium
Zinc

Serving size; 100 g (3.5 oz)
0.6 mg
255 mg
5.73 mg
392 mg
642 mg
813 mg
4.34 mg

Source: USDA Nutrient Database.

3. Background on Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid
(DHA)
Eicosapentaenoic acid (EPA, 20:5 n-3) and docosahexaenoic acid (DHA,
22:6 n-3) are n-3 PUFAs that can be obtained directly from the diet or through
conversion from ALA through a series of elongase and desaturase reactions (Figure 2)
(Poulsen et al., 2007). EPA and DHA are precursors to a variety of metabolites which
regulate the fatty acid composition of skeletal compartments (Watkins et al., 2001). In
comparison to ALA, EPA and DHA are quickly incorporated into cellular phospholipid
membranes and can initiate more potent biological effects (Simopoulos, 1999).
Dietary sources of EPA/DHA include fatty fish, fish oils, and algae (Table 4)
(USDA Nutrient Data Laboratory, 2008).
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Figure 2. Metabolism of N-3 Polyunsaturated Fatty Acids.
Table 4. Dietary Sources of Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid
(DHA).
EPA/DHA (g)

Source (3.5 oz serving)
Salmon
Mackerel
Sardines
Trout
Microalgae Oil (1 capsule)

2.2

1.2
1.0
1.0
0.345

The dietary sources of EPA/DHA utilized in our research were fatty fish (salmon)
and microalgae oil and these sources are further discussed below.
a. Importance of Salmon Salmon is a fatty fish that is a rich source of
EPA and DHA. Since marine-based diets provide a direct source of EPA/DHA, there is
no concern over competition for enzymes in order to convert ALA to EPA/DHA. Each
serving of salmon (3.5 oz) yields approximately 2.2 g of EPA/DHA. Salmon also has a
low n-6: n-3 ratio and reduced saturated fat content (Weaver et ah, 2008). Out of the four
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most commonly farmed fish in the US, salmon and trout were found to have the most
favorable levels of EPA/DHA and monounsaturated fatty acid to PUFA ratios (Weaver et
ah, 2008).
Numerous epidemiological studies have been conducted showing the
cardioprotective effects of fish intake on reducing sudden cardiac death (Kris-Etherton et
ah, 2002). It is believed the cardioprotective effects of fish intake could extend to
skeletal health as well. The American Heart Association recommends at least two
servings of fatty fish per week, along with other n-3 rich foods. While salmon intake is
recognized as beneficial to human health, environmental pollutants such as
polychlorinated biphenyls and other organochlorine toxins have made some clinicians
doubt the safety of advising the general population, especially pregnant and lactating
mothers, on routine salmon intake. Recent surveys have shown that farmed salmon is
more toxic than wild salmon. However, there is still debate over how much farmed
salmon is safe for human consumption (Covington, 2004).
b. Importance ofMicroalgae and Microalgae Oil Microalgae, also
known as microphytes, are usually found in freshwater and marine systems. With over
20,000 species, they are unicellular organisms that can exist individually or cohabitate in
groups. Microalgae are the primary feeding material for marine species and are nutrient
dense in vitamins and n-3 PUFAs, EPA and DHA (Geppert et al., 2006).
Microalgae oil supplements contain approximately 0.345 g EPA/DHA per
capsule. EPA/DHA-rich microalgae oil provides a great alternative to fish oil in that it is
organic, vegan, and free of heavy metals or toxins. Safety assessments conducted on
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Schizochytrium sp., a popular microalgae species used to produce microalgae oil, showed
no genotoxic potential in human serum lymphocyte samples (Hammond et ah, 2002).
Due to the relative safety and accessibility of microalgae oil, many studies have
been conducted to investigate the potential health benefits of this EPA/DHA-rich oil. An
animal study by Sukenik et al. (1994) showed that weanling rats fed a 10% microalgae
diet for 2 wks observed a significant increase in n-3 PUFA liver and tissue fatty acid
composition. Results suggest that microalgae oil does get absorbed at the cellular level
and can be used as a nutritional source of long chain n-3 PUFAs. In a double-blind,
placebo-controlled, parallel trial, healthy vegetarians consumed either a placebo diet of
olive oil or experimental diet with microalgae oil (0.94 g DHA/d) in order to observe its
effect on cardiovascular outcomes (Geppert et ah, 2006). Results showed that microalgae
supplementation improved cardiovascular outcomes, including lowering plasma
triacylglycerol levels. Since microalgae oil is a rich source of EPA/DHA, it is believed
the protective effects of this oil will help delay the onset and progression of other chronic
diseases, including accelerated bone resorption. Further research is warranted in this area
as the amount of purified forms of microalgae oil is being made more accessible to the
general public.
4. Studies on ALA and EPA/DHA and Bone Health
a. Animal Studies with ALA The majority of studies investigating the
effects of n-3 PUFAs on bone maintenance have been conducted on animals, using a
wide range of models including growing to ovariectomized models. In order to
investigate the effects of an ALA-rich flaxseed oil diet on bone turnover, obese and
insulin-resistant rats were used for a 9-wk trial (Mollard et ah, 2005). While bone
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mineral density did not significantly change, prostaglandin E2 levels did decrease. Low
levels of prostaglandin E2 inhibit the activation of receptor-activated nuclear-kappa B
ligand (RANKL), a protein which promotes bone resorption (Coetzee et ah, 2006).
In contrast, another animal study suggested an ALA-rich diet had no effect on
skeletal health. Cohen et al. (2005) fed weanling male and female mice 10% flaxseed oil
diets for 10 wks. There were no changes in levels of inflammatory cytokines or lumbar
bone mineral density (Table 5). These mixed results suggest that further studies are
needed in order to ascertain the role of ALA-rich diets on bone maintenance.
b. Animal Studies with EPA/DHA Animal studies showing the beneficial
effects of EPA and DHA on skeletal health include a 5-wk trial by Sakaguchi et al.
(1994). This study showed that ovariectomized rats put on a low-calcium diet and then
supplemented with EPA (11% of total fat as EPA) had increased bone weight and
strength in comparison to the control group without EPA supplementation. In another
study by Sun et al. (2003), ovariectomized rats were put on 20% casein or soy protein
diet and supplemented with either 5% com oil or fish oil. After 16 weeks, rats on the
com oil diet had increased bone loss while those on the fish oil diet had lower levels of
TNF-a levels and IL-2, pro-inflammatory cytokines which are associated with increased
bone resorption. Liu et al. (2004) used Japanese quail to investigate the effect of
menhaden oil (5% of diet) on skeletal health. After 7 months, results showed higher bone
mineral density and collagen crosslink levels for quail supplemented with menhaden oil.
In agreement with these studies, Shen et al. (2006) showed that gonad-intact male rats fed
an EPA/DHA-rich diet (190 g menhaden oil and 10 g com oil) for 20 weeks had
increased levels of bone-specific alkaline phosphatase, a bone formation marker. These
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results indicate that there may be a protective effect of EPA/DHA on bone health, but
these findings need to be explored further (Table 5).
While numerous intervention studies have indicated EPA/DHA exert protective
effects on bone maintenance, other studies have yielded conflicting results. Green et al.
(2004) showed that male rats fed EPA/DHA-rich menhaden oil (57% of total fat) for 35
days had increased femur bone mineral density. However, significantly reduced levels of
osteocalcin, a bone formation marker, were observed as well. It is believed a longer
study trial might have yielded different results for osteocalcin levels. Poulsen & Kruger
(2006) used ovariectomized rats to assess the effect of EPA supplementation on bone
maintenance. During the 9-wk trial, low (4-4.5% of total fat) and high doses (40-47.5%)
of EPA ethyl ester were administered to experimental groups at 0.1 g and 1.0 g/kg rat
body weight per day, respectively. Study findings indicate that the low dose group
observed no changes on bone mass while the high dose group had a significant reduction
in bone mineral content. The adverse effects could have been attributed to the lack of
DHA supplementation, which has been observed as being more protective for
ovariectomized animals (Table 5) (Poulsen et al., 2007).
While research shows that adequate levels of n-3 PUTAs can regulate bone
turnover, the ratio of n-6 to n-3 PUFAs may play a vital role in how bone remodeling is
influenced. A balanced ratio of n-6: n-3 is necessary for proper development, prevention
of chronic disease, and long-term optimal health (Weiss et al., 2005).
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Table 5. Summary of Intervention Studies in Animals Investigating the Role of N-3
PUFAs on Bone Maintenance.
Study

Animal

Diet

Study Period

Results

Sakaguchi et al.
(1994)
Watkins et al.
(2000)

OVX rats

Low calcium
and EPA
n-6 to n-3 ratios
(1.19:1.2.6:1,
9.8:1, and
23.8:1)
Fish oil

35 days

| Bone weight;
f Bone strength
t BSAP for
diets with
higher n-3
PUFA content
l TNF-a and
IL-2; Possible
protective
effect.
| Femur bone
mineral density;
l Osteocalcin;

Male rats

Sun et al. (2003) OVX rats

6 weeks

16 weeks

Green et al.
(2004)

Male rats

Fish oil

35 days

Liu et al. (2004)

Japanese quail

Menhaden oil

7 months

Cohen et al.
(2005)

Growing male
and female
mice
Obese and
insulinresistant rats
OVX rats

Flaxseed oil

10 weeks

Flaxseed oil

9 weeks

Low and high
doses of EPA
Menhaden oil

9 weeks

Mollard et al.
(2005)
Poulsen &
Kruger(2006)
Shen et al.
(2006)

Watkins et al.
(2006)

Gonad-intact
male rats

OVX rats

Low PUFA vs.
High PUFA

20 weeks

12 weeks

f BMD and
collagen
crosslinks
No effect

| PGE2;
Possible
protective effect
| BMD in high
dose group
t BSAP;
Possible
protective effect
t Femur BMD
in High PUFA
diet; High
PUFA diet may
be protective.

PYD-pyridinoline; BMD-bone mineral density; BSAP-bone-specific alkaline phosphatase; PGE2prostaglandin E2; GLA-gamma linolenic acid; PUFA-polyunsaturated fatty acids; OVX-ovariectomized.
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Watkins et al. (2000) used male rats in a 6-wk trial to compare the effects of diets
with four ratios of n-6 to n-3 (1.19:1. 2.6:1, 9.8:1, and 23.8:1) on biomarkers of bone
turnover. Safflower oil and menhaden oil were used to achieve the proper ratios. Results
showed increased alkaline phosphatase activity, a bone formation marker, for diets with
higher n-3 PUFA content. Watkins et al. (2006) conducted a 12-wk trial on
ovariectomized rats to assess the effects of a high n-3 PUFA (5:1) versus low n-3 PUFA
(10:1) diet on bone health using DHA-rich single cell oil. Study results show that the
high n-3 PUFA diet increased femur bone mineral density. These results indicate that
high DHA supplementation is beneficial and can help promote bone conservation (Table
5).

c. Human Studies with ALA Despite strong evidence from animal studies
supporting the protective effects of n-3 PUFAs on bone health, relatively few studies
have been conducted in humans. There are only a few published randomized, controlled
feeding studies which compare the effects of an ALA-rich plant-based diet to an
EPA/DHA-rich marine-based diet.
The first randomized, controlled feeding study investigating the effect of plantbased n-3 PUFAs on bone turnover was conducted by Griel et al. (2007). In this 3period, crossover study, 23 participants were randomly assigned to each diet for 6 weeks:
1) control diet (7.7% LA, 0.8 % ALA), 2) LA diet (12.6% LA, 3.6 % ALA), and 3) ALA
diet (10.5% LA, 6.5 % ALA). The main sources of ALA came from walnuts and
flaxseed oil. Study findings showed that the ALA diet significantly lowered levels of
serum n-telopeptide, a marker of bone resorption (2007).
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This indicates that a plant-based ALA-rich diet may reduce bone resorption when
steady bone formation is occurring (Table 6).
Table 6. Summary of Intervention Studies in Humans Investigating the Role of N-3
PUT As on Bone Maintenance.
Study

Subjects

Van Papendrop et
al. (1995)

40 osteoporotic
patients

Kruger et al.
(1998)

Diet (Daily
Intake)
4 g fish oil

Study
Period
16
weeks

65 postmenopausal
women

6 g long chain
PUFA-rich oil
(3.6 g LA, 480
mg GLA, 240
mg EPA, and
180 mg DHA)
along with 600
mg of calcium

36
months

| Lumbar spine
bone mineral
density.

Bassey et al.
(2000)

43 pre- and 42 post
menopausal
women

4g primrose oil,
Ig calcium, 440
mg fish oil

1 year

No significant
changes in bone
markers.

Dodin et al. (2005)

Post menopausal
women

40 g flaxseed oil

1 year

No significant
changes in bone
mineral density.

Grid et al. (2007)

23 subjects

37 g walnuts, 15
g walnut oil, 20
g flaxseed oil
(2400 kcal diet)

6 weeks

| NTX; ALA
may exert a
protective effect
on bone
metabolism

Results
| Osteocalcin;
Fish oil may
exert a
protective effect
on bone health.

GLA-gamma linolenic acid; PUFA-polyunsaturated fatty acids; NTX-n-telopeptide; ALA-alpha linolenic
acid.

In another supplemental study, menopausal women were given either the wheat
germ placebo or 40 g of flaxseed oil/d for 12 months (Dodin et al., 2005). Results from
the study showed no significant changes in lumbar spine or femoral neck bone mineral
content. Due to these conflicting results, further randomized, controlled studies need to
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be carried out in order to identify the beneficial effects of dietary ALA on skeletal health
in humans.
d. Human Studies with EPA/DHA Human trials supporting dietary long
chain n-3 PUFA and bone health include the one by Van Pappendrop et al. in which 10
osteoporotic patients administered fish oil (4 g fish oil/d) over 16 weeks showed
significant increase in osteocalcin and procollagen levels, accepted markers of bone
formation (1995). In another study by Kruger et al. (1998), 65 postmenopausal women
were either administered a placebo or experimental capsules [6 g long chain PUFA-rich
oil (3.6 g LA, 480 mg GLA, 240 mg EPA, and 180 mg DHA) along with 600 mg of
calcium] for 36 months. Results showed that participants on the experimental capsules
had increased lumbar spine bone mineral density. In contrast, pre- and post-menopausal
females who were either given Efacal (4g primrose oil, Ig calcium, and 440 mg fish oil)
or the placebo for one year observed no significant changes in bone turnover or bone
mineral density (Bassey et al., 2000) (Table 6).
C. Mechanisms of Action Influencing Bone Maintenance
Research indicates the following proteins, hormones, and growth factors may play
a vital role in how ALA and EPA/DHA may exert protective effects on bone
maintenance.
1. Receptor-activated nuclear-kappa B ligand (RANKL) and Osteoprotegerin
(OPG)
Receptor-activated nuclear-kappa B ligand (RANKL) is a membranebound protein belonging to the TNF-ligand family. RANKL is produced and expressed
on the cell surface of osteoblast cells and its function includes stimulating osteoclastic
differentiation/maturation and preventing osteoclast apoptosis (Kwan et al., 2004).
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RANKL induces osteoclastogenesis by binding to its receptor, receptor activator of
nuclear factor-kappa B (RANK), expressed on osteoclast precursor cells. RANKLRANK binding increases the number of activated osteoclasts which leads to bone
resorption (Figure 3). Mature osteoclast cells can express RANK in order to enhance
bone-resorbing activity as well (Bilezikian et ah, 2002).
Osteoprotegerin (OPG) is a soluble decoy receptor that is secreted by osteoblasts
cells. OPG can inhibit osteoclastogenesis by binding to RANKL, thereby inhibiting its
interaction and binding to RANK (Vega et ah, 2007). The physiological effects of OPGRANKL binding prevent the final stages of osteoclast differentiation/maturation and
increases osteoclast apoptosis, thereby reducing bone resorption (Kwan et ah, 2004). In a
cross-sectional study by Indridason et al. (2005), OPG levels correlated with serum levels
of bone formation marker, osteocalcin, in a healthy population of men and women. In a
double-blind, placebo-controlled trial by Bekker et al. (2001), a single subcutaneous dose
of OPG was given to postmenopausal women in order to assess its effect on bone
resorption marker, N-telopeptide (NTX). After 4 days, mean NTX levels decreased by
80% with an OPG dose of 3.0 mg/kg body wt. Even after 6 wks, mean values of NTX
were still 14% lower than at baseline. Both these studies indicate that OPG may be
protective against net bone loss.
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Figure 3. Formation of Osteoclasts
2. Insulin-like Growth Factor System
During osteoclastic bone activity, insulin-like growth factors present in the
bone matrix can be secreted to exert autocrine/paracrine signaling activities which result
in promoting bone and matrix development (Watkins et al., 2001). These growth factors
include insulin-like growth factor-1 (IGF-1) and its binding protein, insulin-like growth
factor binding protein-3 (IGFBP-3). IGF-1 is a polypeptide that is structurally similar to
pro-insulin. This bone-promoting peptide regulates the effect of growth hormone on
various target tissues, including bone (Toussirot et al., 1998). IGFBP-3 is a major
binding protein that helps activate the bone-promoting function of IGF-1 (Bilezikian et
al., 2002).
In order for bone formation to occur, growth hormone stimulates the production
of IGF-1 from its main production site, the liver. The majority of IGF-1 is bound to
IGFBP-3, which is generated by osteoblasts. The IGF-1/ IGFBP-3 complex circulates in
the plasma to interact with cell surface receptors on skeletal cells in order to elevate
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levels of bone-forming proteins and hormones. This stimulates osteoblast function and
proliferation, resulting in bone formation or growth (Figure 4) (Bilezikian et ah, 2002).

Figure 4. Bone Formation by IGF-1 and IGFBPs
In a cross-sectional study using postmenopausal women, there was no observed
relationship between IGF-1 and bone mineral density (Collins et ah, 1998). However,
there was a significant positive correlation between IGF-1 and bone formation markers,
osteocalcin and bone-specific alkaline phosphatase. In a case-control study with
ankylosing spondylitis (AS) patients, a rheumatic disease associated with accelerated
bone loss, circulating IGF-1 and IGFBP-3 levels were measured to assess osteoblast
function. Study results indicated no significant change in IGF-1 levels. However, serum
levels of IGFBP-3 were statistically lower in AS patients than that of healthy participants
(Toussirot et ah, 1998). Since IGFBP-3 is a key cofactor in enhancing bone-promoting
proteins and hormones, lowered levels observed in AS patients may play a role in
impaired osteoblast function which can limit bone formation. Further studies are needed
in order to assess the effects of increased n-3 PUFA intake on IGF-1 and it major binding
protein, IGFBP-3.
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3. Interleukin-6 (IL-6) and Tumor Necrosis factor-a (TNF-a)
Interleukin-6 (IL-6) is a cytokine that stimulates osteoclast formation and
bone resorption through increasing downstream effectors that result in elevating the
production of RANKL. Tumor necrosis factor-a (TNF-a) is a multi-functional cytokine
that acts in a synergistic fashion with IL-6 to upregulate RANKL production in order to
stimulate osteoclast differentiation and maturation (Figure 5) (Ragab et ah, 2002). In an
animal study by Komine et ah (2001), human TNF-a was observed to significantly
increase the number of preosteoclast-like cells in rat cultures. After 24 hours, the
production of RANKL significantly increased as well.
These pro-inflammatory cytokines are potent stimulators of osteoclastogenesis
and have been linked to inducing the pathogenesis of bone diseases such as osteoporosis
(Salari et ah, 2008).
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Figure 5. Role of IL-6 and TNF-a in Formation of Osteoclasts
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4. 1,25-dihydroxyvitamin D3 [l,25-(OH)2] and Parathyroid Hormone (PTH)
Another mechanism of action in which n-3 PUFAs may affect bone
turnover is through 1,25-dihydroxyvitamin D3 [l,25-(OH)2] and parathyroid hormone
(PTH), systemic hormones that induce bone resorption. Bone resorption is regulated by
osteoclasts, which are indirectly stimulated by PTH. The binding of PTH to osteoblasts
increases expression of receptor-activated nuclear-kappa B ligand (RANKL) and
downregulates OPG mRNA expression in animal cell cultures (Watkins et al., 2001). It
is believed that l,25-(OH)2 and PTH stimulates the binding of RANKL to its receptor,
RANK, which promotes osteoclastogenesis and minimizes osteoclast apoptosis (Poulsen
et al., 2007).
While RANKL and RANK binding induce osteoclastogenesis, RANKL and OPG
binding has been shown to reduce osteoclast levels and bone resorption (Lark & James,
2002).

D. Conclusions
The current research available involving the protective effects of dietary n-3
PUFAs, especially ALA and EPA/DHA, on bone maintenance is minimal and results
from existing studies are conflicting. There is a need for further research in this area
using strong study design and methodology. Additionally, little is known about the exact
mechanism of action by which these n-3 PUFAs affect bone remodeling. Potential
mechanisms of actions need to be identified to explore why ALA and EPA/DHA are
protective and whether these n-3 PUFAs illicit similar effects on bone maintenance.
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CHAPTER 3
METHOD

This study was part of two previous larger intervention trials assessing n-3 PUFA
intake on surrogate outcomes for heart disease (Rajaram et ah, 2009, Sabate et ah, 2009).
A. Subjects
Participants from both studies were recruited from the local Loma Linda area
including LLU, LLU Medical Center, Loma Linda VA Hospital, markets, and nearby
colleges. A multi-phase process was used to carefully screen participants which included
1) completing an introductory screening form 2) attendance at an informational meeting
held by a senior investigator 3) ensuring that participants met all study criteria 4)
individual interviews with two research investigators for final approval and 5)
participants signing an IRB approved consent form.
Participants included in the studies had: (a) no prior affliction with hypertension,
atherosclerosis, or other metabolic diseases, (b) serum cholesterol levels between 160300 mg/dL, (c) serum triglyceride below 250 mg/dL for the Fish and Walnut Study and
below 300 mg/dL for the Omega-3 Study, (d) body mass index below 30 kg/m2, (e) no
weight fluctuations within the past six months, (f) no intake of serum-altering lipid
medications, and (g) age range between 20-70 years for both studies.
For the Fish-Walnut Study, the number of participants completing all three diet
trials was 25 (12 females and 13 males). For the Omega-3 Study, the total number
completing all three diet phases was 24 (9 females and 15 males).
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B. Study Design
Both studies were part of larger intervention trials investigating the effects of
dietary n-3 PUFAs on cardiovascular disease outcomes. The secondary objectives of
these carefully monitored feeding studies were to assess the effects of plant (ALA rich)
versus marine (EPA/DHA rich) sources of n-3 PUFAs on biomarkers of bone turnover.
Feeding trial procedures and techniques were comparable to prior feeding studies
conducted by the Department of Nutrition at Loma Linda University (LLU) (Haddad et
al., 2006; Sabate et al., 2005; Zambon et al., 2000; Sabate et al., 1993).
The Fish-Walnut Study which was completed in 2005 was a controlled, single
blind, randomized trial using healthy participants under controlled conditions (Rajaram et
al., 2009). This study used a Latin-square crossover design and included three diets: (1)
control, (2) EPA/DHA rich diet (salmon), (3) and ALA rich diet (walnuts). After a one
week run-in phase, each participant was assigned to the control, EPA/DHA rich diet, or
ALA rich diet for four weeks each (Table 7). Blood draws were conducted at the
Department of Nutrition Assessment Laboratory (LLU) and serum samples were stored at
-80°C in the Nutrition Biochemical Laboratory. Twelve-hour urine collections were
collected and stored at the Nutrition Biochemical Laboratory.
The Omega-3 Study concluded recently (May 2008) (Sabate et al., 2009). This
study is a 4x3 incomplete crossover trial design including four diets: (1) control (no
supplementation), (2) ALA diet (flaxseed oil/walnuts), (3) EPA/DHA diet (micro algae
oil), and (4) combination diet (flaxseed oil/walnuts/micro algae oil). Each study period
will be eight weeks each and include a washout period of four to six weeks between diets
(Table 1). Blood draws and 24-hour urine collections adhere to protocol similar to those
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from the Fish-Walnut Study. Subjects in both studies signed the IRB approved informed
consent forms.
Table 1. Fish-Walnut Study and Omega-3 Study Experimental Designs
Time Sequence
Fish/Walnut Study

Omega-3
Study

Weeks

Weeks

1

1

Run-in Period

2-5

2-9

Diet Trial 1

Blood drawn at the
start and on two
alternate days at the
end of Diet Trial 1.

6

10-13

Free Period

Wash-out

7-10

14-21

Diet Trial 2

Blood drawn on two
alternate days at the
end of Diet Trial 2.

11

22-25

Free Period

Wash-out

12-15

26-33

Diet Trial 3

Blood drawn on two
alternate days at the
end of Diet Trial 3.

Diet Trial

Comment

C. Diet Protocol
The Fish-Walnut Study included three diets: (1) control, (2) EPA/DHA rich diet
(salmon), (3) and ALA rich diet (walnuts) [Table 2]. The Omega-3 Study included four
diets: (1) control (no supplementation), (2) EPA/DHA diet (micro algae oil), (3) ALA
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diet (flaxseed oil/walnuts), and (4) combination diet (flaxseed oil/walnuts/micro algae
oil) [Table 3].
Participants from the Fish-Walnut Study and the Omega-3 Study obtained all meals
from research staff. For the Fish-Walnut Study, participants consumed breakfast and
dinner on the premises at the Nutrition Research Kitchen at LLU. All lunches and snacks
were packed in the morning and given to each participant at breakfast. Saturday meals
were packed and distributed to participants during Friday dinner. All meals and
beverages were carefully weighed by trained research staff. For the Omega-3 Study,
participants consumed dinners on the premises at the LLU Campus Cafeteria. All
breakfast, lunch, and snacks were given to participants at dinner for the next day.
Saturday meals were packed and distributed to participants during Friday dinner.
For both the Fish-Walnut Study and the Omega-3 Study, all diets followed the
2005 Dietary Guidelines for Americans concerning acceptable distribution ranges for
macronutrients (32-33% of calories from total fat, 8-9% of calories from saturated fat,
and less than 300 mg/day from dietary cholesterol). All experimental diets were
isocaloric and ranged from 1500 kcal to 3600 kcal to accommodate for the energy needs
of each participant. For the Fish-Walnut Study, the main sources of n-3 rich foods were
EPA/DHA rich salmon and ALA rich walnuts. For the Omega-3 Study, the main sources
of n-3 rich foods were EPH/DHA rich microalgae oil and ALA rich flaxseed oil and
walnuts. For the latter study, all menu plans adhered to a lacto-ovo vegetarian diet
containing no meat products.
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Table 2. Fish-Walnut Study Experimental Diets for Average 2400 Kcal Diets.
Experimental Diets

Description

1) Control

No ALA or EPA/DHA rich foods

2) EPA/DHA rich diet (Salmon)

227g per 2400 kcal/week
(2 servings/wk)

3) ALA rich diet (Walnuts)

45 g per 2400 kcal/week
(5-6 times/wk)

Note: The Fish-Walnut Study followed the 2005 Dietary Guidelines for Americans concerning acceptable
distribution ranges for macronutrients. The breakdown of macronutrients included: 32-33% of calories
from total fat, 8-9% of calories from saturated fat, less than 300 mg/day from dietary cholesterol, 55-65%
of calories from carbohydrates, and 10-15% of calories from protein.

Table 3. Omega-3 Study Experimental Diets for Average 2400 Kcal Diets.
Experimental Diets

Description (2400 kcal diet)

1) Control

No ALA or EPA/DHA rich foods

2) EPA/DHA rich diet
(Micro algae oil)

1.40/5.04 g EPA/DHA per wk

3) ALA rich diet
(Flaxseed oil and walnuts)

42-49 g flaxseed oil per wk
10 g walnuts (3 times/wk)

4) Combination diet
(Flaxseed oil, walnuts, and micro algae oil)

42-49 g flaxseed oil per wk
10 g walnuts (3 times/wk)
1.40/5.04 g EPA/DHA per wk

Note: The Omega-3 Study followed the 2005 Dietary Guidelines for Americans concerning acceptable
distribution ranges for macro nutrients. This breakdown of macronutrients included: 32-33% of calories
from total fat, 8-9% of calories from saturated fat, less than 300 mg/day from dietary cholesterol, 55-65%
of calories from carbohydrates, and 10-15% of calories from protein.
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D. Sample Size
The calculated sample sizes used to detect mean differences in coronary risk
factors for the Fish-Walnut Study and the Omega-3 Study were 18 and 24 participants
(statistic: 0.05; power-90%), respectively. Griel et al. (2007) included 23 participants in
their randomized, 3-trial crossover design to detect statistical significance for the effect of
dietary plant-based n-3 PUFAs on bone turnover in humans. Since an analysis of
covariance (ANCOVA) mixed-effect model will be used, this will require a smaller
sample size in order to achieve greater power (Borm et al., 2007).
In Post Hoc analyses, using data from another published intervention trial (Griel
et al., 2007), power of 80% would be obtained for bone markers CTX, OC, and PINP if
15, 17, and 21 participants completed the study, respectively (statistic: 0.05, effect size:
0.20). For the following bone markers, the probability is more than 80% that the study
will detect significant differences in treatment if the actual effect size is 20%.
E. Data Collection
For the Fish-Walnut Study, each participant had blood drawn at the end of the
run-in phase and at the end of each diet trial. For the Omega-3 Study, each participant
had blood drawn once at the beginning of each diet trial and then at the end of each diet
trial. Blood draws were conducted at the Department of Nutrition Assessment
Laboratory (LLU) and serum samples were stored at -80°C in the Nutrition Biochemical
Laboratory. Urine collections from both studies have been stored at the Nutrition
Biochemical Laboratory at -80°C.
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F. Laboratory Analyses
All serum samples were packed in dry ice to be delivered to Dr. Subburaman
Mohan’s laboratory at the Loma Linda Petitis VA Hospital (Loma Linda, CA) for
biochemical determination. All serum radioimmunoassays and enzyme-linked
immunoassays were performed in this laboratory. Serum concentrations of each bone
marker were determined in duplicate runs at baseline and after each experimental diet.
For both studies, the bone resorption marker assessed was serum C-telopeptide
(CTX). This collagen-based marker is released from the matrix following bone loss and
is one of the most accurate indicators in which to assess bone resorption (Eastell &
Hannon, 2008; De Vemejoul, 1998). CTX was measured using the Serum Crosslaps
ELISA Assay (Immunodiagnostic Systems Limited, Boldon Business Park, Boldon, UK)
which quantifies the degradation products of C-terminal telopeptides of Type 1 collagen
in human serum.
The Serum Crosslaps ELISA Assay uses the competitive binding characteristics
of biotinylated and peroxidase conjugated monoclonal antibodies against human CTX on
the P-isomerized sequence of EKAHD-f3-GGR. Along with the application of
streptavidin, standards, controls, and unknown samples were treated with specific
mixtures of biotinylated and peroxidase conjugated antibodies in microtitre wells.
Following incubation and washing, chromogenic substrate tetramethylbenzidine (TMB)
was added as a visualizing agent. Absorbance is measured spectrophotometrically
between 450-650nm. CTX concentrations were determined by interpolation of the
quadratic curve using absorbance and CTX concentrations from standards and controls.
The intra- and interassay coefficients of variation were <6% and <10%, respectively.
36

Bone formation markers assessed include serum procollagen type I N-terminal
propeptide (PINP) and osteocalcin (OC). These biomarkers reflect osteoblast activity and
are the most specific and sensitive bone formation markers available (Eastell & Hannon,
2008).
PINP is the propeptide that must be cleaved for Type 1 procollagen to develop
into collagen molecules and fibres. This propeptide can be found and measured in
circulation and its concentration reflects the rate of Type 1 collagen development and
early bone formation. UNiQ PINP RIA (Orion Diagnostica, Espoo, Finland) was the
radioimmunoassay used to measure serum PINP. This radioimmunoassay uses a known
quantity of labeled PINP and unknown quantity of unlabelled PINP to competitively
bind to limited sites located on polyclonal rabbit anti-PINP antibody. An additional
antibody against rabbit IgG is added to test tubes in order to detach PINP bound to
antibody from that of free PINP. The I125 radioactive material present in free PINP
remaining in the supernatant is measured using a gamma counter. The quantity of
labeled PINP in test tubes is inversely proportional to the quantity in PINP serum
samples. Unknown serum PINP sample concentrations are obtained from a calibration
curve, with calibrators provided by UniQ PINP RIA which contain 0-250 pg/1 PINP.
The intra- and interassay coefficients of variation were 6.5-10.2% (12-173 pg/L) and 6.09.8% (12-167 pg/L), respectively.
Osteocalcin (OC) is a protein found in the skeletal matrix and is generated by
osteoblasts, which make it an important indicator of bone formation. Serum OC
concentrations were measured using N-MID Osteocalcin ELISA (Nordic Bioscience
Diagnostics, Herlev, Denmark). This assay uses the competitive binding characteristics
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of biotinylated and peroxidase conjugated monoclonal antibodies against human OC to
measure the N-terminal-Mid fragment region. In addition to the application of
streptavidin, standards, controls, and unknown samples were treated with specific
mixtures of biotinylated and peroxidase conjugated antibodies in microtitre wells.
Following incubation and washing, chromogenic substrate tetramethylbenzidine (TMB)
was added as a visualizing agent. Absorbance was measured spectrophotometrically
between 450-650nm. OC concentrations are determined by interpolation of the
calibration curve using absorbance and OC concentrations from standards and controls.
The intra- and interassay coefficients of variation were <4% and <7%, respectively.
G. Statistical Analyses
Statistical analyses were done by a trained statistician using SAS software,
version 9.1 (SAS Institute Inc, Cary, NC). Data are reported as least squares mean +
standard error. An analysis of covariance (ANCOVA) mixed-effect model was used to
minimize within-group error variance and confounding, with control for baseline
measurements and period effect (phase 1, 2, 3). Subject nested within sequence was
included into the model as a random effect. The Kenward-Roger method was used to
estimate denominator degrees of freedom for tests of fixed effects. Tukey-Kramer HSD
tests were performed to assess significant pair-wise differences among the control,
EPA/DHA-rich, and ALA-rich diets. A pre-determined level of statistical significance
was set at p<0.05.
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Abstract
Recent scientific evidence suggests that polyunsaturated fats (PUFAs), especially
n-3 PUFAs, exert protective effects on bone. The objective of this study was to
investigate the effects of dietary n-3 PUFAs from plant versus marine sources on
biochemical markers of bone turnover. This study was a controlled, single blind,
randomized trial using a Latin-square crossover design. Twenty-five (12 females and 13
males) healthy participants completed the study which included three diets: [1] control,
[2] ALA-rich diet (45 g of walnuts/2400 kcal/wk), and [3] EPA/DHA-rich diet (227 g of
salmon/wk). After a 1-week run-in phase, each participant was randomly assigned to a
diet for 4 weeks each. Each diet trial was separated by a 1-week washout period.
Biochemical markers of bone turnover [c-telopeptide (CTX); procollagen Type I Nterminal propeptide (P1NP); and osteocalcin (OC)] were analyzed in serum. Plasma
phospholipid (PL) levels of EPA/DHA and ALA were significantly higher for
participants on the fish and walnut diet (p < 0.0001), respectively. There were no
significant changes in concentrations of serum CTX and OC among the three diets (p >
0.05). There was a significant negative association between serum P1NP and age (p =
0.005). In addition, there was a negative association with plasma PL DHA levels and age
(p = 0.04). Our findings suggest that both an ALA-rich diet and an EPA/DHA-rich diet
did not alter biochemical markers of bone resorption (CTX) and formation (P1NP and
OC) in this study design.
Keywords: alpha -linolenic acid (ALA); eicosapentaenoic acid (EPA): docosahexaenoic
acid (DHA); c-telopeptide (CTX); procollagen Type I N-terminal peptide (P1NP);
osteocalcin (OC)
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Introduction
The National Osteoporosis Foundation approximates that 44 million Americans
are at risk or already afflicted with osteoporosis, a condition of reduced bone mass that is
prevalent among postmenopausal females (Haas & Moore, 2007). While the numbers are
staggering, medical experts believe that osteoporosis and other bone-related diseases can
be prevented or delayed by increasing certain nutrients in the diet (Javaid & Holt, 2008;
Love, 2003). Recent scientific evidence suggests that polyunsaturated fats (PUFAs),
especially n-3 PUFAs, exert protective effects on bone (Grid, et al., 2007; Shen, Yeh,
Rasty, Li, & Watkins, 2006; Watkins, Li, & Seifert, 2006). Human studies show that n-3
PUFA regulate osteoblast and osteoclast production, cells which play a significant
biological role in bone formation and resorption (Baggio, et al., 2005). a-linolenic acid
(ALA, 18:3 n-3) is a parent compound for long-chain n-3 PUFA metabolism and yields
eicosapentaenoic acid (EPA, 20:5 n-3) and docosahexaenoic acid (DHA, 22:6 n-3)
through a series of elongase and desaturase reactions. EPA and DHA are precursors to a
variety of metabolites that regulate the fatty acid composition of skeletal compartments
(Salari, Rezaie, Larijani, & Abdollahi, 2008; Watkins, Li, Lippman, & Seifert, 2001).
ALA is essential for human growth and development and must be obtained through the
diet primarily from plant sources (Burdge, 2006). EPA and DHA are predominately
obtained through marine sources (Poulsen, Moughan, & Kruger, 2007).
While there is a growing body of evidence from epidemiological (Hogstrom,
Nordstrom, & Nordstrom, 2007; Weiss, Barrett-Connor, & von Muhlen, 2005; Zalloua, et
al., 2007) and animal studies (Liu, Veit, & Denbow, 2004; Shen, et al., 2006; Watkins,
Li, Allen, Hoffmann, & Seifert, 2000) on the bone health promoting effects of n-3
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PUFAs, to date only very few human studies (Grid, et al., 2007; Van Papendrop,
Coetzer, & Kruger, 1995) have investigated the effects of ALA or EPA/DHA on bone
health. In the only randomized, controlled feeding study conducted to date on the role of
ALA on bone turnover, Grid et al. (Grid, et al., 2007) showed that an ALA rich diet (37
g walnuts and 15 g walnut oil/day for 2400 kcal diet) significantly lowered levels of
serum N-telopeptide, a marker of bone resorption following 6 weeks intervention. In
contrast, menopausal women given 40 g of ALA-rich flaxseed oil/d for 1 year showed no
significant changes in lumbar spine or femoral neck bone mineral content (Dodin, et al.,
2005). Studies using EPA/DHA also report inconsistent findings, with one study
observing increases in bone formation marker osteocalcin (OC) with 4 g/d intake of fish
oil after 16 weeks (Van Papendrop, et al., 1995), while another study observed no effect
even after 1 year of intervention (Bassey, Littlewood, Rothwell, & Pye, 2000; Dodin, et
al., 2005).
These conflicting findings warrant further research in order to establish if there is
a beneficial effect for ALA and EPA/DHA on skeletal health outcomes. Also, ours is one
of the first controlled feeding studies in humans to compare an ALA-rich diet to that of
an EPA/DHA-rich diet. In addition, while most human studies have focused on either
bone formation or resorption markers, we measured both types of markers to identify the
association between n-3 PUFAs and bone turnover. The aim of this study was therefore
to investigate the effects of dietary n-3 PUFAs from plant versus marine sources on
biochemical markers of bone turnover in healthy adults.
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Subjects and Methods
Subjects
Twenty-seven normal to dyslipidemic participants were initially invited to
be part of this study but two dropped out due to time constraints. The number of
participants completing all three experimental trials was 25 (12 females and 13 males).
Participants included in the study were non-smoking adults between the ages of 23 and
65 y (mean + SD, 33.2 + 2.4). Body mass index (BMI) and total cholesterol of
participants at baseline were 24.8 + 0.7 kg/m2 and 5.41 + 0.2 mmol/L, respectively.
Participants included in the studies had: (a) no prior affliction with hypertension,
atherosclerosis, or other metabolic diseases, (b) serum cholesterol levels between 4.147.77 mmol/L, (c) serum triglyceride below 2.83 mmol/L, (d) body mass index below 30
kg/m2, (e) no weight fluctuations within the past six months, and (f) no intake of serum
lipid altering medications.
Participants were recruited from the local Loma Linda area including Loma Linda
University (LLU) and surrounding areas. A multi-phase process was used to carefully
screen participants which included: (1) completing an introductory screening form, (2)
attendance at an informational meeting held by a senior investigator, (3) ensuring that
participants met all study criteria, (4) individual interviews with two research
investigators for final approval, and (5) participants signing an IRB approved consent
form. During the study, all participants were advised to maintain their habitual level of
physical activity.
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Study Design
This was part of a larger intervention study investigating the effects of
dietary n-3 PUFAs on risk factors of cardiovascular disease (Rajaram, Haddad, Mejia, &
Sabate, 2009). The secondary objective of this carefully monitored feeding study was to
determine the effect of plant (ALA-rich) versus marine (EPA/DHA-rich) sources of n-3
PUFAs on biomarkers of bone turnover. The IRB at LLU approved this study and signed
consent forms were collected from each participant.
This study was a controlled, single blind, randomized trial using healthy
participants under controlled conditions. This trial used a Latin-square crossover design
and included three diets: (1) control, (2) ALA-rich diet, and (3) EPA/DHA-rich diet.
After a one week run-in phase, each participant was randomly assigned to one diet for
four weeks each. Each diet trial was separated by a one-week washout period.
Diets
This study included three diets: [1] control (free of nuts and fatty fish), [2]
ALA-rich diet (45 g of walnuts/2400 kcal/wk), and [3] EPA/DHA-rich diet (227 g of
salmon/wk). The fatty acid composition of an average 2400 kcal diet for all treatments is
reported in Table 1.
Participants from this study obtained all meals from research staff. Participants
consumed breakfast and dinner on the premises at the Nutrition Research Kitchen at
LLU. All lunches and snacks were packed in the morning and given to each participant
at breakfast. Saturday meals were packed and distributed to participants during Friday
dinner. Trained research staff carefully weighed all meals and beverages.
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All diets followed the 2005 Dietary Guidelines for Americans concerning
acceptable distribution ranges for macronutrients (32-33% of calories from total fat, 8-9%
of calories from saturated fat, and less than 300 mg/day from dietary cholesterol)
(Services, 2005). All experimental diets were isocaloric and ranged from 1500 kcal to
3600 kcal to accommodate for the energy needs of each participant. The main sources of
n-3 rich foods were EPA/DHA-rich salmon and ALA-rich walnuts.
Serum Collection and Analyses
Each participant had blood drawn at the end of the run-in phase and at the
end of each diet trial. All blood draws were taken by venipuncture and participants were
advised to fast 12 hours before each collection. Blood draws were conducted at the
Department of Nutrition Assessment Laboratory and serum samples were stored at -80°C
in the Nutrition Biochemical Laboratory at LEU. Plasma phospholipid (PL) fatty acid
composition was measured by Lipomics Laboratory (Sacramento, CA). Bone marker
analyses were performed in duplicate runs at baseline and after each experimental diet at
Loma Linda Petitis VA Hospital (Loma Linda, CA).
C-telopeptide (CTX) was measured using the Serum Crosslaps ELISA Assay
(Immunodiagnostic Systems Limited, Boldon Business Park, Boldon, UK) that quantifies
the degradation products of C-terminal telopeptides of Type 1 collagen in human serum.
This collagen-based marker is released from the matrix following bone loss and is one of
the most accurate indicators in which to assess bone resorption (De Vemejoul, 1998;
Eastell & Hannon, 2008; Rosen, et al., 2000). The Serum Crosslaps ELISA Assay uses
the competitive binding characteristics of biotinylated and peroxidase conjugated
monoclonal antibodies against human CTX on the p-isomerized sequence of EKAHD-p45

GGR. The intra- and interassay coefficients of variation were <6% and <10%,
respectively.
Serum procollagen type I N-terminal propeptide (PINT) and osteocalcin (OC)
were assessed as bone formation markers as these two reflect osteoblast activity and are
the most specific and sensitive bone formation markers available (Eastell & Hannon,
2008). Serum P1NP was measured using the UNiQ P1NP RIA (Orion Diagnostica,
Espoo, Finland). This radioimmunoassay uses both labeled and unlabelled P1NP to
competitively bind to limited sites located on polyclonal rabbit anti-PINP antibody. The
intra- and interassay coefficients of variation were 6.5-10.2% (12-173 pg/L) and 6.09.8% (12-167 pg/L), respectively.
Osteocalcin (OC) is a protein found in the skeletal matrix and is generated by
osteoblasts, which make it an important indicator of bone formation (Bilezikian, Raisz, &
Rodan, 2002). Serum OC concentrations were measured using N-MID Osteocalcin
ELISA (Nordic Bioscience Diagnostics, Herlev, Denmark). This assay measures both
intact OC and the N-Mid fragment region. The intra- and interassay coefficients of
variation were <4% and <7%, respectively.
Statistical Analyses
A trained statistician using SAS software, version 9.1 (SAS Institute Inc,
Cary, NC) conducted the statistical analyses. Data are reported as least squares (LS)
mean + standard error. An analysis of covariance (ANCOVA) mixed-effect model was
used to minimize within-group error variance and confounding with control for baseline
measurements and period effect (phase 1, 2, and 3). Subject nested within sequence was
included into the model as a random effect. The Kenward-Roger method was used to
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estimate denominator degrees of freedom for tests of fixed effects. Tukey-Kramer HSD
tests were performed to assess significant pair-wise differences among the control,
EPA/DHA-rich, and ALA-rich diets. A mixed model approach was also used to
determine the association between bone markers (CTX, PINP, and OC) and plasma PL
fatty acids (LA, ALA, EPA, and DHA), adjusting for treatments and period effect. A
pre-determined level of statistical significance was set at p<0.05.
Results
The fatty acid composition of treatment diets from chemical analyses showed that
the amount of EPADHA and ALA in the diet increased for participants on the fish and
walnut diet, respectively (Table 1). Plasma PL fatty acid analyses at the conclusion of
each experimental diet for EPA, DHA, ALA, and linoleic acid (LA) were significantly
different (Table 2). Levels of EPA/DHA and ALA were significantly higher for
participants on the fish (p < 0.0001) and walnut (p < 0.0001) diet, respectively.
Mean concentration of serum bone markers CTX, PINP and OC are given in
Table 3. Results did not significantly differ among the three diets for serum CTX and
OC, even after adjusting for age and gender (p > 0.05). No significant changes were
observed among the three diets (p > 0.05) for serum PINP. However, there was a
significant negative association between PINP levels and age (p = 0.005) (Figure 1).
There was no significant association between plasma PL levels of ALA, EPA,
DHA, and LA on biochemical markers of bone turnover (CTX, PINP, and OC) (p >
0.05). However, there was a significant negative association between plasma PL DHA
levels and age (p = 0.04) (Figure 2).
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Discussion
We investigated the effects of dietary n-3 PUFAs from plant versus marine
sources on biochemical markers of bone turnover in healthy adults. Our findings show
that there were no significant differences between ALA-rich diets and EPA/DHA-rich
diets on bone formation markers, P1NP and OC, and bone resorption marker, CTX. In
contrast, Grid et al. (Grid, et ah, 2007) showed a significant reduction in bone resorption
marker, NTX, with an ALA-rich diet. The protective effect observed in their trial may be
attributed to the longer 6-week intervention compared to the 4-wk intervention used in
our study. Also, Grid et al. had a 3-week washout period between diets which can
minimize time and carryover effects compared to the weekend washout we had in our
study. The amount of ALA used in their study was also much higher (259 g of walnuts,
105 g of walnut oil, 140 g flaxseed oil/wk for 2400 kcal diet) compared to 226 g of
walnuts/wk in our trial. While the amount used in our study has dearly documented
cardioprotective effects (Rajaram, et al., 2009), it may not be enough to provide bone
health promoting effects. Our subjects were also much younger (average age 33 y)
compared to those that participated in the Grid et al. (Griel, et al., 2007) study (average
age 49.3 y). This is significant because the age of a person determines the degree of bone
turnover and this may be a predictor of any potential differences that can be seen with
changes in diet (Claudon, et al., 2008).
Results indicate excellent adherence to dietary protocol as participants on the fatty
fish and walnut diets had significantly higher plasma PL levels of EPA/DHA and ALA,
respectively. However, the incorporation of EPA/DHA into plasma phospholipids
following the ALA rich diet was not adequate. It is possible that any influence of n-3
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PUFA on bone markers may be a function of DHA levels in the plasma phospholipids or
red blood cell membrane. In fact, a study in young men (Hogstrom, et ah, 2007)
demonstrated that of the different n-3 PUFAs, DHA is the one positively associated with
BMD and bone mineral accrual. The optimal incorporation of DHA may require an
intervention longer than 4 weeks or the absolute amount of EPA/DHA fed to the subjects
may need to be higher.
While the amount of DHA in the red blood cell membrane is critical in
influencing BMD, the lowering of the n-6 to n-3 fatty acid ratio may also be protective of
BMD in older adults (Weiss, et ah, 2005). Previously, Griel et al (Grid, et ah, 2007)
showed that an ALA rich diet lowered a serum marker of bone resorption. However, in
this study, the n-6: n-3 ratio of the ALA rich diet was 1.6:1, much lower than the 4:1 that
we accomplished in our study. Future studies are needed to investigate the possible role
of absolute levels of DHA and the ratio of n-6: n-3 fatty acids which can exert protective
effects on bone.
The significant negative association between plasma PL DHA concentration and
age suggest conversion to longer chain n-3 PUFAs may be reduced with advancing age,
possibly due to lower A-6 desaturase activity (Albertazzi & Coupland, 2002). Since
adequate DHA intake is critical for optimal health, future recommendations for direct
sources of DHA consumption or supplementation may be necessary, especially for vegan
and vegetarians who have lower DHA status compared to omnivores (Saldanha, Salem,
& Brenna, 2009; Sanders, 2009). In addition, there was a significant negative correlation
with P1NP levels and age, which supports other research suggesting a decline and
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eventual plateau in concentrations of bone formation in adults between 30-50 years of
age (Bhattacharya, Rahman, Sun, & Fernandes, 2007; Pi, et al., 2006).
Other human studies involving the protective effects of dietary n-3 PUFAs on
bone maintenance are minimal and results by existing studies are conflicting. Van
Papendrop et al. (Van Papendrop, et al., 1995) and Kruger et al. (Kruger, Coetzer, de
Winter, Gericke, & van Papendorp, 1998) showed significant increases in osteocalcin
levels and lumbar bone mineral density, respectively. The 3-year trial by Kruger et al.
has shown it may take longer than a single year to observe significant changes in bone
mineral density. One year supplemental studies with ALA-rich flaxseed oil or EPA/DHA
rich fish oils showed no significant changes in bone mineral density which supports this
assumption (Bassey, et al., 2000; Dodin, et al., 2005). While both supplemental studies
have a longer intervention period, the nature of the study design is prone to numerous
confounding factors and limits interpretations for cause and effect.
While human intervention studies have yielded mixed results, findings from
epidemiological studies (Chen, Ho, & Lam, 2009; Hogstrom, et al., 2007; Weiss, et al.,
2005; Zalloua, et al., 2007) and animal studies (Liu, et al., 2004; Sakaguchi, Morita, &
Murota, 1994) continue to warrant further research in this area. Epidemiological studies
show a positive association between dietary n-3 PUFA and BMD in young men
(Hogstrom, et al., 2007) and increased seafood consumption and BMD among women
aged 25-64 y (Zalloua, et al., 2007). Increase in dietary sea fish intake correlated with
higher BMD and lower osteoporosis risk in postmenopausal women aged 48-63 y (Chen,
et al., 2009). Also, low dietary ratio of n-6: n-3 fatty acid was associated with higher
BMD at the hip in men and women > 45 y of age (Weiss, et al., 2005).
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Most of the animal studies suggest that n-3 fatty acids can help with both
increasing bone formation and preventing resorption (Liu, et ah, 2004; Sakaguchi, et ah,
1994; Sun, et ah, 2003). The influence on bone markers may be mediated in part by the
effects of n-3 PUFA on inflammatory cytokines (Mollard, Gillam, Wood, Taylor, &
Weiler, 2005) which inhibits the activity of receptor-activated nuclear kappa B ligand
(RANKL), a protein that promotes bone resorption (Coetzee, Haag, & Kruger, 2007).
However animal studies do not tease out the differences between the effects of ALA and
EPA/DHA and have limited application to human bone metabolism.
Our study was an attempt to establish the effects of ALA and EPA/DHA rich diets
on markers of bone turnover using a rigorous study design in human adults. Even though
our study did not show significant differences due to diet on the selected bone markers,
further studies are still warranted. Clearly these future studies need to consider the
optimal dose, the population to study with respect to status of bone metabolism (example
young adults versus postmenopausal women), length of intervention, dietary ratio of n6:n-3 fatty acid, and the use of normal subjects versus those at risk for osteoporosis. The
possible differences in effect between ALA and EPA/DHA with respect to bone health
outcomes will also need to be addressed again because of its public health relevance.
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Table 1. The Fatty Acid Composition of Treatment Diets from Chemical Analyses in
Healthy Adults1.
Fatty acids

Control

EPA/DHA Diet

ALA Diet

Total Fat (% en)

23.7

22.4

29.4

SFA (% en)

7.9

7.3

6.6

MUFA (% en)

9.8

9.2

8.7

PUFA (% en)

3.8

3.8

11.9

EPA + DHA (g)
ALA (g)
LA(g)
LA:ALA ratio

0.25

0.64
0.79
8.6
10.8:1

0.32

0.87
9.1
10:1

5.9
28.6
4.8:1

SFA (saturated fatty acids); MUFA (monounsaturated fatty acids); LA (linoleic acid).
Tor 2400 kcal diets. Chemical analyses were conducted at Covance Laboratories (Madison, WI).
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Table 2. Plasma Phospholipid Fatty Acid Composition of Healthy Participants at the
Conclusion of Each Experimental Diet1.
Fatty Acid *
(mol %)
Monounsaturated
Fatty Acid
(MUFA)

Control

EPA/DHA Diet

ALA Diet

P-Value2

11.99 (0.19)3

11.53 (0.19)3a

9.49(0.19)4b

<0.0001

PUFA
Linoleic Acid
(LA)

39.37 (0.47)3

41.01 (0.48)4a

43.28 (0.47)4b

<0.05

19.44 (0.57)3

18.41 (0.57)3a

24.96 (0.57)4b

<0.0001

ALA

0.18 (0.02)3

0.17 (0.02)3a

0.42 (0.02)4b

<0.0001

EPA

0.73 (0.12)3

2.06 (0.12)4a

0.72(0.12)3b

<0.0001

DHA

2.98 (0.15)3

5.69 (0.15)4a

2.92 (0.1S)313

<0.0001

1 LS mean + SE
2 P-value for the main effect of diet using a mixed model approach. Mean values within a row with varying
superscript numbers are different from the control diet. Mean values within a row with varying
alphabetical superscripts have significant pair-wise differences among diets.
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Table 3. Mean Concentrations of Serum C-telopeptide (CTX), Procollagen Type I Nterminal Propeptide (P1NP), and Osteocalcin (OC) at the End of Each Experimental
Diet1.

Diet
Control

CTX (pg/ml)
LS Mean
SE
0.5147
0.01798

P1NP (pg/1)
LS Mean
SE
48.7638
2.1415

OC (pg/ml)
LS Mean
SE
15.1072
0.5822

EPA/DHA

0.4979

0.01799

50.2840

2.1439

14.9788

0.5824

ALA

0.5058

0.01797

50.4539

2.1391

15.0700

0.5819

'There was no significant diet effect among the experimental diets.
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Figure 1. The Association between Bone Formation Marker Serum PINP and Age for the
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Abstract
Objective: To investigate the effects of dietary n-3 polyunsaturated fat from plant versus
marine sources on biochemical markers of bone turnover.
Design: This study was a controlled, single blind, randomized trial using a 4x3 Latinsquare crossover design.
Subjects/Methods: Twenty-four (9 females and 15 males) healthy participants completed
the study. This study included four diets: [1] control, [2] ALA-rich diet (42-49 g flaxseed
oil/wk; lOg walnuts, 3 times/week), [3] EPA/DHA-rich diet (1.40/5.04 g EPA/DHA from
microalgae oil/wk), and [4] combination diet (including both ALA and EPA/DHA diets).
After a 1-week run-in phase, participants were randomly assigned to a diet for 8 weeks
each. Biochemical markers of bone turnover [c-telopeptide (CTX); procollagen Type INterminal propeptide (P1NP); and osteocalcin (OC)] were analyzed in serum at the end of
each diet period in both studies.
Results: There were no significant changes in serum CTX, P1NP, and OC among the
four diets (p > 0.05). There was a significant negative association between age and CTX
(pO.OOOl), P1NP (p=0.0006), and OC (p=0.002). There was also a negative association
between CTX with RBC LA and ALA and a positive correlation between CTX and RBC
DHA (p<0.05).
Conclusion: Our findings suggest that both an ALA-rich diet and an EPA/DHA-rich diet
did not alter biochemical markers of bone resorption (CTX) and formation (P1NP and
OC) in healthy adults in this study design.
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Introduction
In the United States, the estimated healthcare costs in hospital utilization,
Medicare, and lost productivity for the management and treatment of bone joint diseases
approximates $ 15 billon dollars/y (Gardner, Demetrakopoulos, Shindle, Griffith, & Lane,
2006; Gueldner, Grabo, Newman, & Cooper, 2008). Due to the high morbidity and
mortality rates associated with compromised bone integrity, preventive strategies are
essential in helping to reduce the onset or progression of bone joint diseases. Diet can
directly influence bone turnover, which makes adequate nutrition an important therapy in
helping to reduce accelerated bone resorption (Fernandes, Lawrence, & Sun, 2003;
Rizzoli, 2008).
Research indicates that the intake of n-3 polyunsaturated fatty acids (PUFAs) may
have bone health promoting effects (Grid, et al., 2007; Weiss, et al., 2005). N-3 PUFAs,
specifically a-linolenic acid (ALA, 18:3 n-3), eicosapentaenoic acid (EPA, 20:5 n-3), and
docosahexaenoic acid (DHA, 22:6 n-3), are of special interest because they help regulate
the fatty acid composition of skeletal cells (Salari, et al., 2008; Watkins, Li, Lippman, &
Feng, 2003). These n-3 PUFAs contain more than one point of unsaturation which
enhances cell membrane fluidity. This increases the number and potency of cell surface
receptors and enzymes critical for optimal interactions with bone-generating growth
factors and hormones (Poulsen, et al., 2007).
While there is scientific agreement concerning the cardioprotective effects of
dietary n-3 PUFA intake, relatively few human studies have been conducted to date on
the potential protective effects of these fatty acids on bone turnover (Kris-Etherton, et al.,
2002; Paschos, Magkos, Panagiotakos, Votteas, & Zampelas, 2007; Sodergren, et al.,
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2001; Watkins, et al., 2001). The few intervention studies available suggest that ALA
and EPA/DHA rich diets may help increase biomarkers of bone formation and reduce
bone resorption (Griel, et ah, 2007; Kruger, et al, 1998; Van Papendrop, et al, 1995).
However, other human studies have shown no changes in bone turnover or bone mineral
density (Bassey, et al, 2000; Dodin, et al, 2005). While there is convincing evidence
from epidemiological and animal studies indicating not only the cardioprotective effects
of n-3 PUFA but also bone health effects (Hogstrom, et al, 2007; Sakaguchi, et al, 1994;
Shen, et al, 2006; Watkins, et al, 2000; Weiss, et al, 2005), there is sparse information
from intervention studies on the role of n-3 PUFA in promoting bone health. Thus, the
objective of this study was to examine the effects of plant (ALA rich) versus marine
(EPA/DHA rich) sources of n-3 PUFAs on biomarkers of bone turnover. This study will
address if plant and marine-based diets are comparable in how they influence bone
turnover.
Materials and Methods
Study Design
This study was part of a larger intervention trial assessing n-3 PUFA
intake on surrogate outcomes for heart disease (Sabate', Wien, Oda, Rajaram, & Haddad,
2009). The secondary aim was to assess the effects of ALA rich versus EPA/DHA rich
sources of n-3 PUFAs on biochemical markers of bone turnover in healthy adults.
Feeding trial protocol was comparable to previous feeding studies conducted by the
Department of Nutrition at Loma Linda University (LLU, CA) (Rajaram, et al, 2009).
This study was a single blind, 4x3 incomplete crossover trial including four diets:
(1) control (no supplementation), (2) ALA diet (flaxseed oil/walnuts), (3) EPA/DHA diet
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(micro algae oil), and (4) combination diet (flaxseed oil/walnuts/micro algae oil). There
was an initial 1-wk run-in phase to assess participant’s adherence to dietary protocol.
Study periods were 8 wks each and included a washout of 4-6 wks between study
periods. Dietary compliance was assessed by weekly examination of individual
participant diaries and through direct observation by research staff at each meal on
campus. This study was approved by the Institutional Review Boards (IRB) at Loma
Linda University and at Loma Linda Pettis Veteran Affairs (VA) hospital.
Subjects
The total number of healthy participants completing all three diet periods
was 24 (9 females and 15 males, mean age=41 y) (Table 1). Participants were recruited
from the Loma Linda area, including nearby hospitals and colleges. Participants that met
all study criteria and received the highest commitment scores for adhering to dietary
protocol were selected and these subjects each signed IRB-approved informed consent
forms.
Inclusion criteria consisted of: (a) no prior affliction with hypertension,
atherosclerosis, or other metabolic diseases, (b) serum cholesterol levels between 160300 mg/dL, (c) serum triglyceride below 300 mg/dL (d) body mass index below 30
kg/m2, (e) stable weight within the past six months, (f) no intake of serum lipid altering
medications, (g) age range between 20-70 years, (h) adherence to a lacto-ovo vegetarian
diet throughout the study, and (i) no known food allergies to ALA and EPA-DHA-rich
foods. All participants were non-smokers and maintained the same level of physical
activity throughout the study.
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Study Diets
This study included four diets: [1] control (no ALA or EPA/DHA-rich
foods), [2] EPA/DHA diet (1.40/5.04 g EPA/DHA from microalgae oil/wk), [3] ALA diet
(42-49 g flaxseed oil/wk; 10 g walnuts (3 times/wk)), and [4] combination diet (1.40/5.04
g EPA/DHA/wk; 42-49 g flaxseed oil/wk; 10 g walnuts (3 times/wk)). All menu plans
were lacto-ovo vegetarian meals containing no meat products. The linoleic acid
(LA)/ALA ratio of the control and EPA/DHA diet was 10:1. The LA/ALA ratio for the
ALA and combination diet was 2:1. The nutrient composition of sample 2400 kcal diets
from chemical analyses for each diet treatment is reported in Table 2.
This was an entirely controlled feeding study; therefore, participants obtained all
meals from research staff. Participants consumed dinners on the premises at the LLU
Campus Cafeteria. All breakfast, lunch, and snacks were given to participants at dinner
for the next day. All Saturday meals were packed and distributed to participants during
Friday dinner. In order to increase dietary compliance, all meals were monitored by at
least one senior investigator.
All diets followed the Dietary Guidelines for Americans (2005) and Dietary
Reference Intakes for adults concerning acceptable distribution ranges for macronutrients
(32-33% of calories from total fat, 8-9% of calories from saturated fat, and less than 300
mg/day from dietary cholesterol). The control, EPA/DHA-rich, and ALA-rich diets were
isocaloric and ranged from 1500 kcal to 3300 kcal. The main sources of n-3 rich foods
were EPH/DHA-rich microalgae oil and ALA-rich flaxseed oil and walnuts. All menu
plans adhered to a 9-day weekday and 2-day weekend menu cycle with lacto-ovo
vegetarian meals provided throughout the study.
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Data Collection and Analyses
Each participant had blood drawn at baseline and at the end of each diet
trial. Blood draw clinics were conducted at the Department of Nutrition Assessment
Laboratory and serum samples were stored at -80°C in the Nutrition Biochemical
Laboratory (LLU). The Nutritional Assessment Core at the University of California,
Davis (CA), conducted all blood lipid analyses. Lipomics Laboratory (Sacramento, CA)
measured erythrocyte membrane fatty acid composition at the end of each treatment
period.
Biochemical determination of all bone markers occurred at Loma Linda Pettis VA
Hospital (Loma Linda, CA). Serum concentrations of each bone marker were determined
in duplicate runs at baseline and after each experimental diet. Bone resorption marker ctelopeptide (CTX) was measured using the Serum Crosslaps ELISA Assay
(Immunodiagnostic Systems Limited, Boldon Business Park, Boldon, UK) that quantifies
the degradation products of C-terminal telopeptides of Type 1 collagen in human serum.
The intra- and interassay coefficients of variation were <6% and <10%, respectively.
Bone formation marker procollagen type I N-terminal propeptide (P1NP) was
measured using the UNiQ P1NP RIA (Orion Diagnostica, Espoo, Finland). This
radioimmunoassay uses both labeled and unlabelled P1NP to competitively bind to
limited sites located on polyclonal rabbit anti-PINP antibody. The intra- and interassay
coefficients of variation were 6.5-10.2% (12-173 pg/L) and 6.0-9.8% (12-167 pg/L),
respectively.
Bone formation marker osteocalcin (OC) was measured using N-MID Osteocalcin
ELISA (Nordic Bioscience Diagnostics, Herlev, Denmark). This assay measures the N68

Mid fragment region of OC in human serum. The intra- and interassay coefficients of
variation were <4% and <7%, respectively.
Statistical Analyses
A trained statistician using SAS software, version 9.1 (SAS Institute Inc,
Cary, NC) performed the statistical analyses. Data are reported as least squares mean +
standard error. A mixed-effect model was used that included a random-effect term for
subjects nested in sequence, a fixed-effect term for period and treatment, and covariate
term representing the amount of specific n-3 PUFAs (ALA and/or EPA/DHA) in each
respective diet. The Kenward-Roger method and Tukey-Kramer HSD tests were
performed to estimate denominator degrees of freedom for tests of fixed effects and to
evaluate significant pair-wise differences among the diets, respectively. A mixed model
approach was also used to evaluate the association between bone markers (CTX, PINP,
and OC) with individual red blood cell (RBC) membrane fatty acids (LA, ALA, EPA,
and DHA), adjusting for treatments and period effect. A pre-determined level of
statistical significance was set at p<0.05.
Results
Nutrient Analyses and Dietary Compliance
The nutrient composition of treatment diets from chemical analyses
(Covance Laboratories, Madison, WI) is reported in Table 2. Sample 2400kcal diets
were slightly higher in caloric value than that of those obtained from calculated values
using the Nutrition Data System for Research software which approximated 2372 kcal
and 2384 kcal for the control/EPA+DHA and ALA/combination diet, respectively
(version 2006, Nutrition Coordinating Center, Minneapolis, MN). However, percentage
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of total fat (-30%), saturated fat (<10%), and trans fatty acids (<1%) were in the
appropriate range and adhered to the 2005 Dietary Guidelines for Americans and Dietary
Reference Intakes for adults. The ALA-rich diet including flaxseed oil had 8.59 g ALA/d
and <0.05 g EPA/DHA/d for a sample 2400 kcal diet. The EPA/DHA-rich diet including
microalgae oil contained 0.92g of EPA/DHA/d and 2.87 g ALA/d. The LA: ALA ratio
for the control and EPA/DHA diets was approximately 9.3:1. The LA: ALA ratio for the
ALA and combination diets was 2.5:1. Both ratios were extremely close to the planned
LA: ALA ratio analysis of 10:1 and 2:1 for the control/EPA+DHA and ALA/combination
diets, respectively.
Dietary compliance was assessed through erythrocyte membrane fatty acid
composition for each participant at the end of every diet treatment (Table 3). There were
no significant differences between diets in mol % of PUPA, linoleic acid (LA), and
monounsaturated fatty acid (MUFA) values (p>0.05). As expected, the EPA (pO.OOOl)
and DHA (p<0.05) concentrations were significantly higher in the EPA/DHA and
combination diets in comparison to the control diet. The ALA and combination diets had
significantly higher concentrations of ALA in comparison to the other treatment diets
(pO.OOOl). Results indicate excellent adherence to dietary protocol from study
participants.
N-3 PUFAs and Bone Markers
Mean serum CTX, PINP, and OC concentrations among the control,
EPA/DHA, ALA, and combination diets are reported in Table 4. There was no
significant diet effect or pair-wise differences among treatment diets, even after adjusting
for age and gender (p > 0.05).
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Correlation between Bone Markers with n-3 PUFAs and Age
A mixed model approach was used to examine the association between
bone markers (CTX, PINP, and OC) and individual n-3 PUFAs (Table 5). There was a
significant negative association between serum CTX with red blood cell (RBC)
membrane LA (p=0.0143) and ALA (p^.0477). There was a significant positive
association with serum CTX and RBC membrane DHA (p=0.0385). Even after adjusting
for gender, results were still significant.
A mixed model approach was also used to investigate an association between age
and bone markers (CTX, PINP, and OC). There was a significant negative association
between age and bone markers CTX (pO.OOOl), PINP (p=0.0006), and OC (p=0.0019)
(Table 5).
Discussion
This study compared the effects of plant versus marine sources of n-3 PUFAs on
bone turnover in healthy adults, providing approximately 8.6 g of ALA and 1 g EPA +
DHA/d for the ALA and EPA/DHA diets, respectively. Even after adjusting for age and
gender, there was no significant diet effect or pair-wise differences among treatment diets
with respect to bone markers CTX, PINP, and OC. While these amounts have been
observed to promote cardioprotective effects, it appears that this does not extend to
influencing bone turnover in our study subjects (Paschos, et al., 2007; Rajaram, et ah,
2009). One possible explanation could be attributed to the amount of n-3 PUFAs
provided. Previously a 6-wk feeding trial by Oriel et al. (2007) providing a significantly
higher dose (17 g ALA from walnuts/walnut oil and flaxseed oil/d) showed a significant
reduction in bone resorption marker, N-telopeptide.
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Another reason for not observing any effects may be due to the duration of the
intervention. An 8-wk trial may be insufficient time in which to observe changes in
bone turnover, especially for a healthy adult population (Hogstrom, et al., 2007;
Macdonald, New, Golden, Campbell, & Reid, 2004). Van Papendrop et al. (1995)
showed significant increases in bone formation marker OC after 16 wk of fish oil
supplementation at 4 g fish oil/d. After 3 y of long chain PUFA-rich oil supplementation
(3.6g LA, 480mg GLA, 240 mg EPA, and 180mg DHA), Kruger et al. (1998) observed
an increase in lumbar spine bone mineral density and decrease in bone resorption marker
deoxypyridinoline. This last study indicates that a lower dose may be more protective
over a longer intervention period. Also, the majority of our subjects were in their mid
20’s to early 50’s, with only 2 participants over 55 y of age. This study did not include
young adolescents or many elderly adults who are at a biologically have a higher rate of
bone turnover (Crofton, Evans, & Stephen, 2003; Sambrook, et al., 2006) .
Consistent with our findings, others have shown no significant effect of n-3
PUFA with regards to changes in bone turnover. In 1 y studies using EPA/DHA-rich fish
oil and ALA-rich flaxseed oil, no significant changes in markers of bone turnover were
identified (Bassey, et al., 2000; Dodin, et al., 2005). These observations are in conflict
with the findings from epidemiological (Hogstrom, et al., 2007; Weiss, et al., 2005) and
animal studies (Shen, et al., 2006; Watkins, et al., 2000), which indicate a stronger
association between n-3 PUFA and bone promoting effects. Further studies are therefore
warranted to identify the appropriate dose, duration of intervention, and target
populations which would be most suitable to study the effects of n-3 PUFA on markers of
bone turnover.
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We observed a significant negative association between serum CTX and RBC
membrane LA and ALA. Lower concentrations of LA and ALA were associated with
higher levels of bone resorption marker, CTX. Other research also supports that LA and
ALA promote bone growth, although lower dietary ratios of n-6: n-3 protect bone (Salari
et al., 2008). The plausible mechanism by which lowered concentrations of ALA
correlate with increased bone resorption may be due to prostaglandin E2 (PGE2). PGE2 is
the primary eicosanoid affecting bone metabolism and inhibits the activation of receptoractivated nuclear-kappa B ligand (RANKL), a protein which promotes osteoclastogenesis
(Coetzee, et al., 2007; Tanaka, Nakayamada, & Okada, 2005). In a 9-wk animal study by
Mollard et al. (2005), ALA-rich flaxseed oil diets significantly reduced PGE2 levels.
Dietary intake of ALA may exert an anabolic effect on bone through lowering
concentrations of PGE2 (Poulsen, et al., 2007).
We also observed a Further findings indicate a significant positive association
between RBC membrane DHA and bone resorption marker CTX. However, numerous
studies suggest that higher endogenous DHA levels actually help reduce bone resorption.
Serum phospholipid DHA levels were positively associated with total bone mineral
density in healthy men between 16 and 22 y of age (Hogstrom et al., 2007). In a 12-wk
animal study, a high PUFA diet incorporating DHA-rich single cell oil supplementation
increased femur bone mineral density (Watkins, et al., 2006). These findings indicate
high DHA supplementation is actually beneficial and can help promote bone
conservation. Further research is warranted in order to determine how DHA levels affect
bone turnover.
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There was a significant negative association between age with bone markers
CTX, P1NP and OC. These findings are in agreement with other studies showing a
diphasic effect of age on bone remodeling in specific age groups (Pi, et ah, 2006). In
adulthood, bone resorption and formation markers decline with age, reaching its lowest
levels between 30-50 y (Bhattacharya, et ah, 2007; Eastell, Baumann, Hoyle, &
Wieczorek, 2001; Szulc & Delmas, 2001). The majority of participants in this study
were within this age range, with only 2 participants over 55 y of age (mean age=41).
After the age of 50, studies show that these bone markers actually increase with age due
to high bone turnover in both bone resorption and formation, although bone resorption
usually exceeds bone formation (Claudon, et ah, 2008; Heikkinen, et ah, 1997).
Even though numerous epidemiological and animal studies suggest an association
between increased n-3 PUPA intake and improved skeletal outcomes, there is still
insufficient data from intervention studies to support this or to develop dietary
recommendations for the general public in regards to preventing bone loss (Poulsen, et
ah, 2007; Salari, et ah, 2008). But there is sufficient justification to conduct studies in the
future to clarify the effects of n-3 PUPA on bone and identify potential mechanisms of
action. Enhanced dietary n-3 PUPA intake may be one preventive treatment which could
potentially delay the incidence of accelerated bone resorption by a few years or more
(Salari et ah, 2008). The impact this would have towards reducing healthcare costs and
lost productivity would be tremendous, including improving the quality of life for those
afflicted.
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Table 1. Characteristics of the Participants at Baseline.
Characteristics
N
Age (y)
BMI (kg/m2)
Total Cholesterol (mg/dL)
Triglyceride (mg/dL)
LDL-Cholesterol (mg/dL)
HDL-Cholesterol (mg/dL)

Mean + SE
24

41.0 ± 2.7
25.4 ±0.9
166 ±9.7
106.4 ± 11.8
101.6 ±8.4
42.4+1.9

75

Table 2. The Nutrient Composition of Treatment Diets from Chemical Analyses1.
Nutrients

Diets:
Control, EPA/DHA
10:1 ratio2

Diets:
ALA, Combination
2:1 ratio2

Energy (kcal)

2556
60
12
28
8
<1
8
10

2568
60
12
28
7
<1
9
10

Control: < 0.05
EPA/DHA: 0.20
Control: <0.05
EPA/DHA: 0.72
2.87
26.62
9.3:1

ALA: < 0.05
Combination: 0.20
ALA: < 0.05
Combination: 0.72
8.59
21.86
2.5:1

Carbohydrate (%)
Protein (%)
Total Fat (%)
SFA (%)
Trans Fatty Acids (%)
MUFA (%)
PUFA (%)
EPA (g)
DHA (g)
ALA (g)
LA (g)
LA:ALA ratio

1 Chemical analyses were conducted at Covance Laboratories (Madison, WI). EPA and DHA values were
obtained from the Nutrition Data System for Research (NDSR) (software version 2006, Nutrition
Coordinating Center (NCC), University of Minnesota, Minneapolis, MN).
2Sample 2400 kcal diets.
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Table 3. Red Blood Cell Fatty Acid Composition of Participants at the Conclusion of Each Experimental Diet.
Fatty Add
(mol %)

Control

EPA/DHA Diet

PUFA

37.72 (0.34)

Combination Diet

37.85 (0.34)

ALA Diet
38.13 (0.33)

37.91 (0.34)

P-Value
NS

EPA

0.42 (0.05)

i

0.94 (0.05)2a

1.01 (0.05)2b

1.39 (0.05) 2ab

<0.0001

DHA
ALA
Linoleic Acid (LA)
Monounsaturated
Fatty Acid
(MUFA)

0.45 (0.03) i
0.62 (0.07) i
60.28 (0.39)

1.11 (0.03)2ac
0.64 (0.07)ab
60.69 (0.39)

0.47 (0.03)ab

<0.05

2.10 (0.07)2a
60.24 (0.39)

1.01 (0.03) 2bc
2.00 (0.07)2b
60.07 (0.39)

<0.0001
NS

16.62 (0,28)

16.21 (0,28)

16.62 (0.28)

16.62 (0.28)

NS

Note: Mean values within a row with varying numerical superscript numbers are statistically different from the control diet. Mean values within a row with
the same alphabetical superscripts are statistically different between specific diets (p < 0.05).
-*4

'-a

Table 4. Mean Concentrations of CTX, P1NP, and OC at the End of Each Experimental
Diet1.
Bone Markers
Diet
Control

CTX
0.538 (0.041)

PINP
54.68 (2.96)

OC
18.46(1.13)

EPA/DHA

0.480 (0.041)

51.44 (2.96)

18.01 (1.13)

ALA

0.588 (0.041)

50.10(2.96)

16.34(1.13)

Combination

0.583 (0.041)

50.89 (2.96)

16.91 (1.13)

'LS Mean + SE. There was no significant diet effect among the experimental diets (p>0.05).

78

Table 5. The Association between Bone Markers with Individual n-3 PUFAs and Age1.
Bone Markers

CTX

P1NP

oc

n-3 Fatty Acid
LA

Estimate

P-value

-0.058 (0.023)

0.0143

ALA

-0.419(0.208)

0.0477

EPA

0.068 (0.133)

NS

DHA
Age
LA

0.038 (0.018)
-0.017(0.00345)
0.083 (1.50)

0.0385
<0.0001
NS

ALA

11.18(13.13)

NS

EPA

-11.46 (8.19)

NS

DHA
Age
LA

-1.50(1.13)
-0.909 (0.225)

NS
0.0006

-0.903 (0.614)

NS

ALA

-2.98 (5.32)

NS

EPA

-1.81 (3.36)

NS

DHA

-0.102 (0.463)
-0.429 (0.122)

NS
0.0019

Age

^ven after adjusting for age and gender, results were still significant.
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CHAPTER 6
CONCLUSION

A. Summary and Implication of Findings
The aim of this study was to investigate the effects of dietary n-3 PUFAs from
plant versus marine sources on biochemical markers of bone turnover in healthy adults.
Our controlled feeding studies are the first to compare an ALA-rich diet (walnuts,
flaxseed oil) to that of an EPA/DHA-rich diet (salmon, microalgae oil).
This study was part of two previously concluded larger intervention trials; the
Fish-Walnut Study (Rajaram et al., 2009) and the Omega-3 Study (Sabate' et al 2009).
These two studies were conducted with the primary objective of looking at the effect of
ALA and EPA/DHA rich diets on cardiovascular outcomes. This present study utilized
biological samples collected from these two intervention studies with the objective of
evaluating the effects of the ALA and EPA/DHA rich diets on markers of bone turnover.
In the Fish-Walnut Study, there were no significant changes in serum
concentrations of c-telopeptide (CTX) and osteocalcin (OC) among the three diets
(control, fish, and walnut diet). For serum procollagen type I N-terminal propeptide
(PINP), there was a significant negative association between P1NP levels and age (p =
0.005). There was also a significant negative association between plasma phospholipid
DHA and age (p = 0.04). This significant negative association suggests conversion to
longer chain n-3 PUFAs may be reduced with advancing age, possibly due to lower A-6
desaturase activity (Albertazzi et al., 2002). Since adequate DHA intake is critical for
optimal health, direct sources of DHA consumption or supplementation may be
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necessary, especially for vegan and vegetarian populations (Saldanha et al., 2009;
Sanders et al., 2009).
In the Omega-3 Study, there were no significant changes in serum concentrations
of P1NP and OC among the four diets (control, microalgae oil, flaxseed oil/walnuts, and
combination diet). However, for serum CTX, there was a significant negative association
between CTX with red blood cell (RBC) membrane LA (p=0.0143) and ALA (p=0.0477)
and a positive association with CTX and RBC membrane DHA (p=0.0385). In regards to
age-related differences, there was a significant negative association between age with
bone markers CTX (pO.OOOl), P1NP (p=0.0006), and OC (p=0.0019). This association
between and age and bone markers is in agreement with other studies showing a biphasic
effect of age on bone remodeling in specific age groups (Pi et al., 2006). In adulthood,
bone resorption and formation markers decline with age, reaching its lowest levels
between 30-50 yrs, the range in age distribution of most of our study participants
(Bhattacharya et al., 2007; Eastell et al, 2001).
In addition, the Omega-3 Study assessed serum IGF-1 levels, a bone-promoting
peptide that regulates the effect of growth hormone on various target tissues, including
bone (Bilezikian et al., 2002). In comparing serum IGF-Levels among the four diets,
there was a marginally significant diet effect (p=0.0489). However, no significant
pairwise differences between diets were observed. Our findings show there was a
significant positive association between serum IGF-1 levels and OC (p=.0052) which is
in agreement with other research (Collins et al., 1998). In regards to age-related
differences, there was a significant negative association between serum IGF-1 levels and
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age (p<0.0001) indicating that overall bone formation may be compromised with
advancing age (Kasukawa et al., 2004).
In pooled data analyses including both studies, there was a significant negative
association between serum OC levels and RBC ALA (p=0.04). The same negative
association between OC and RBC membrane ALA was present when subjects were
dichotomized into low and high fatty acid groups based on mean baseline fatty acid
values (p^O.0085) (Appendix 1). In contrast to our findings, other studies have shown no
effect or lower bone resorption with an ALA-rich diet and higher RBC membrane ALA
levels (Griel et al., 2007; Dodin et al., 2005). A possible explanation could be that
conversion of the parent compound ALA to its more biologically active byproducts EPA
and DHA may be minimal, thus limiting the protective effects on bone. There is
evidence suggesting conversion of ALA to EPA/DHA is significantly lower in men,
which may have been a factor, as over half of the participants in both studies were male
(Burdge, 2006).
B. Limitations
Since the primary objectives of the Fish-Walnut and the Omega-3 Study were to
assess the effects of dietary n-3 PUFAs on cardiovascular disease outcomes and not bone
turnover, certain factors in participant selection and study design and methods were not
taken into consideration. In regards to participant selection, limited range in age
distribution may be a reason for not observing changes in bone markers. For this study,
the participants were between 23-65 y of age. This trial did not include young
adolescents or many postmenopausal females who biologically have a higher rate of bone
turnover (Chen et al., 2006; Crofton et al., 2003). In regards to sample size, the initial
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calculated sample size used to detect mean differences in coronary risk factors for this
trial was 18 (statistic: 0.05; power-90%). Fortunately, Post Hoc analyses using data from
the intervention trial by Griel et al. (2007) showed power of 80% was still achieved for
bone markers CTX, OC, and PINP if 15, 17, and 21 participants completed the study,
respectively (statistic: 0.05, effect size: 0.20). This study had 25 participants completing
all three diet treatments which would provide even higher power.
Concerning study design and methods, a study by Mollard & Weiler suggests that
several skeletal biomarkers adhere to a 24-hr circadian rhythm indicating time of
sampling could be important (2007). For instance, bone resorption marker N-telopeptide
levels were found to be highest in the morning and lowest in the afternoon. Fortunately,
twelve-hour fasting blood draws for both studies were collected in the morning. Also,
while the amount used in our study has clearly documented cardioprotective effects
(Rajaram, et al., 2009), it may not be enough to provide bone health promoting effects.
For example, in order to observe changes in bone resorption marker N-telopeptide, Griel
et al. (2007) used a much higher amount of ALA (259 g of walnuts, 105 g of walnut oil,
140 g flaxseed oil/wk for 2400 kcal diet) compared to 226 g of walnuts/wk in our trial.
In addition, a longer duration trial may have yielded results which are in agreement with
previous feeding studies (Kruger et al., 1998; Van Papendrop et al., 1995). A 4-wk trial
may be insufficient time in which to observe changes in bone turnover, especially in
healthy adults (Hogstrom et al., 2007; Macdonald et al., 2004).
C. Conclusions and Future Research
Our study was an attempt to establish the effects of ALA and EPA/DHA rich diets
on markers of bone turnover using a rigorous study design in human adults. Even though
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our study did not show significant differences due to diet on the selected bone markers,
further studies are still warranted. The strong evidence from animal studies and growing
evidence from epidemiological studies and the inconsistent findings in the relatively few
human intervention studies make it imperative that future research be conducted in this
area using rigorous study design.
Recommendations for future research on the dietary effects of n-3 PUFAs on
bone turnover include (1) incorporating a longer study trial and washout period, (2) using
sample populations such as young adults or postmenopausal women with higher rates of
bone turnover, (3) including varied amounts of dietary ALA and EPA/DHA to assess
dose response effects, (4) assessing multiple bone markers of formation and resorption,
(5) examining the significance of varying dietary ratios of n-6:n-3 fatty acid, and (6)
exploring mechanisms of action which may help explain why ALA and EPA/DHA
protect bone maintenance. The relative safety and accessibility of dietary n-3 PUFAs
increases the need for research in this area.

93

REFERENCES
Albertazzi, P., Coupland, K. (2002). Polyunsaturated fatty acids: Is there a role in
postmenopausal osteoporosis prevention. Maturitas, 42, 13-22.
Almario, R.U., Vonghavaravat, V., Wong, R., Kasim-Karakas, S.E. (2001). Effects of
walnut consumption on plasma fatty acids and lipoproteins in combined
hyperlipidemia. American Journal Clinical Nutrition, 74, 72-79.
Baggio, B., Budakovic, A., Ferraro, A., Checchetto, S., Priante, G., Musacchio, E. et al
(2005). Relationship between plasma phospholipid polyunsaturated fatty acid
composition and bone disease in renal transplantation. Transplantation, 80, 13491352.

Barcelo-Coblijn, G., Murphy, E.J., Othman, R., Moghadasian, M.H., Kashour, T., Friel,
J.K. (2008). Flaxseed oil and fish-oil capsule consumption alters human red blood
cell n-3 fatty acid composition: A multiple-dosing trial comparing 2 sources of n3 fatty acid. American Journal Clinical Nutrition, 88, 801-809.
Bassey, E.J., Littlewood, J.J., Rothwell, M.C., Pye, D.W. (2000). Lack of effect of
supplementation with essential fatty acids on bone mineral density in healthy preand postmenopausal women: two randomized controlled trials of Efacal v.
calcium alone. British Journal Nutrition, 83, 629-635.
Bekker, P.J., Holloway, D., Nakanishi, A., Arrighi, M., Leese, P.T., Dunstan, C.R.
(2001). The effect of a single dose of osteoprotegerin in postmenopausal women.
Journal ofBone Mineral Research, 16, 348-360.

94

Bhattacharya, A., Rahman, M., Sun, D., Fernandes, G. (2007). Effect of fish oil on bone
mineral density in aging C57BL/6 female mice. Journal ofNutritional
Biochemistry, 18, 372-379.
Bilezikian, J.P., Raisz, L.G., Rodan, G.A. (eds) (2002) Principles ofBone Biology.
Academic Press: San Diego, CA.
Bloedon, L.T., Szapary, P.O. (2004). Flaxseed and cardiovascular risk. Nutrition Review,
62, 18-27.
Blomhoff, R., Carlsen, M.H., Andersen, L.F., Jacobs Jr., D.R. (2006). Health benefits of
nuts: potential role of antioxidants. British Journal of Nutrition, 96, Suppl 2: S5260.
Burdge, G.C., Calder, P.C. (2005). Conversion of a-linolenic acid to longer-chain
polyunsaturated fatty acids in human adults. Reproduction Nutrition
Development, 45, 581-597.
Burdge, G.C. (2006). Metabolism of a-linolenic acid in humans. Prostaglandins,
Leukotrienes, and Essential Fatty Acids, 45, 161-168.
Calvo, M.S., Eyre, D.R., Gundberg, C.M. (1996). Molecular basis and clinical
application of biological markers of bone turnover. Endocrine Review, 17, 333368.
Chen, J., Tan, K.P., Ward, W.E., Thompson, L.U. (2003). Exposure to flaxseed or its
purified lignan during suckling inhibits chemically induced rat mammary
tumorigenesis. Experimental Biology and Medicine, 228, 951-958.

95

Chen, Y.M., Ho, S.C., Lam, S.S. (2009). Higher sea fish intake is associated with greater
bone mass and lower osteoporosis risk in postmenopausal Chinese women.
Osteoporosis International, [Epub ahead of print].
Cheung, A.M., Tile, L., Lee, Y., Tomlinson, G., Hawker, G., Scher, J. et al (2008).
Vitamin K supplementation in postmenopausal women with osteopenia (ECKO
trial): A randomized controlled trial. Public Library of Science Medicine, 5, el 96.
Claassen, N., Potgieter, H.C., Seppa, M., Vermaak, W.J., Coetzer, H., Van Papendorp,
D.H. et al (1995). Supplemented gamma-linolenic acid and eicosapentaenoic acid
influence bone status in young male rats: Effects on free urinary collagen
crosslinks, total urinary hydroxyproline, and bone calcium content. Bone, 16,
385S-392S.
Claudon, A., Vergnaud, P., Valverde, C., Mayr, A., Klause, U., Gamero, P. (2008). New
automated multiplex assay for bone turnover markers in osteoporosis. Clinical
Chemistry, 54, 1554-1563.
Coetzee, M., Haag, M., Kruger, M.C. (2007). Effects of arachidonic acid,
docosahexaenoic acid, prostaglandin E(2) and parathyroid hormone on
osteoprotegerin and RANKL secretion by MC3T3-E1 osteoblast-like cells.
Journal ofNutritional Biochemistry, 18, 54-63.
Cohen, S.L., Ward, W.E. (2005). Flaxseed oil and bone development in growing male
and female mice. Journal of Toxicology and Environmental Health, 68, 18611870.
Collins, D., Woods, A., Herd, R., Blake, G., Fogelman, L, Wheeler, M. et al (1998).
Insulin-like growth factor-I and bone mineral density. Bone, 23, 13-16.
96

Cornish, S.M., Chilibeck, P.D. (2009). Alpha-linolenic acid supplementation and
resistance training in older adults. Applied Physiology, Nutrition, and Metabolism,
34, 49-59.
Covington, M.B. (2004). Omega-3 fatty acids. American Family Physician, 70, 133-140.
Crofton, P.M., Evans, N., Stephen, R. (2003). Serum CrossLaps compared with other
markers of bone turnover in severely malnourished children before and after
refeeding. Clinical Chemistry, 49, 192-195.
Daun, J.K., Barthet, V., Chromick, T.L., Duguid, S. (eds) (2003) Flaxseed in Human
Nutrition. AOCS Press: Champaign, IL.
De Vemejoul, M.C. (1998). Markers of bone remodeling in metabolic bone disease.
Drugs & Aging, 12, 9-14.
Dodin, S., Lemay, A., Jacques, H., Legare, F., Forest, J.C., Masse, B. (2005). The effects
of flaxseed dietary supplement on lipid profile, bone mineral density, and
symptoms in menopausal women: A randomized, double-blind, wheat germ
placebo-controlled clinical trial. Journal of Clinical Endocrinology and
Metabolism, 90, 1390-1397.
Eastell, R., Baumann, M., Hoyle, N.R., Wieczorek. (eds) (2001) Bone Markers:
Biochemical and Clinical Perspectives. Martin Dunitz Ltd.: United Kingdom,
London.
Eastell, R., Lambert, H. (2002). Diet and healthy bones. Calcified Tissue International,
70, 400-404.

Eastell R, Hannon RA (2008). Biomarkers of bone health and osteoporosis risk.
Proceedings of the Nutrition Society, 67, 157-162.
97

Ermakova, I.P., Buzulina, V.P., Pronchenko, LA., Dudov, N.S., Mininkov, A.S.,
Ponkratova, T.S. (2007). [Level of aminoterminal type 1 procollagen propeptidethe bone formation marker—in the sera of healthy males]. Klinicheskaia
Labomtornaia Diagnostika, 5, 13-15.
Fernandes, G., Lawrence, R., Sun, D. (2003). Protective role of n-3 lipids and soy protein
in osteoporosis. Prostaglandins Leukotrienes Essential Fatty Acids, 68, 361-372.
Gardner, M. L, Demetrakopoulos, D., Shindle, M. K., Griffith, M. H., Lane, J. M. (2006).
Osteoporosis and skeletal fractures. Hospital for Special Surgery Journal, 2, 6269.
Geppert, J., Kraft, V., Demmelmair, H., Koletzko, B. (2006). Microalgal
docosahexaenoic acid decreases plasma triacylglycerol in normolipidaemic
vegetarians: a randomised trial. British Journal ofNutrition, 95, 779-786.
Green, K. H., Wong, S. C., Weiler, H. A. (2004). The effect of dietary n-3 long-chain
polyunsaturated fatty acids on femur mineral density and biomarkers of bone
metabolism in healthy, diabetic and dietary-restricted growing rats.
Prostaglandins Leukotrienes Essential Fatty Acids, 71, 121-130.
Grid, A. E., Kris-Etherton, P. M., Hilpert, K. F., Zhao, G., West, S. G., Corwin, R. L.
(2007). An increase in dietary n-3 fatty acids decreases a marker of bone
resorption in humans. Nutrition Journal, 6, 2.
Gueldner, S.H., Grabo, T., Newman, E.D., Cooper, D.R. (Eds.). (2008). Osteoporosis:
Clinical guidelines for prevention, diagnosis, and management. New York, NY:
Springer Publishing Company.

98

Haas, M. L., & Moore, K. (2007). Osteoporosis: an invisible, undertreated, and neglected
disease of elderly men. Journal ofElder Abuse Neglect, 19, 61-73.
Haddad, E., Jambazian, P., Karunia, M., Tanzman, J., Sabate, J. (2006). A pecanenriched diet increases 5-tocopherol/cholesterol and decreases thiobarbituric acid
reactive substances in plasma of adults. Nutrition Research, 26, 397-402.
Hammond, B. G., Mayhew, D. A., Kier, L. D., Mast, R. W., Sander, W. J. (2002). Safety
assessment of DHA-rich microalgae from Schizochytrium sp. Regulatory
Toxicology and Pharmacology, 35, 255-265.
Heikkinen, A. M., Parviainen, M., Niskanen, L., Komulainen, M., Tuppurainen, M. T.,
Kroger, H., et al. (1997). Biochemical bone markers and bone mineral density
during postmenopausal hormone replacement therapy with and without vitamin
D3: a prospective, controlled, randomized study. Journal of Clinical
Endocrinology and Metabolism, 82, 2476-2482.
Hogstrom, M., Nordstrom, P., Nordstrom, A. (2007). n-3 Fatty acids are positively
associated with peak bone mineral density and bone accrual in healthy men: the
N02 Study. American Journal Clinical Nutrition, 85, 803-807.
Huebner, A. K., Schinke, T., Priemel, M., Schilling, S., Schilling, A. F., Emeson, R. B.,
et al. (2006). Calcitonin deficiency in mice progressively results in high bone
iumoxQx. Journal ofBone Mineral Research, 21, 1924-1934.
Indridason, O. S., Franzson, L., Sigurdsson, G. (2005). Serum osteoprotegerin and its
relationship with bone mineral density and markers of bone turnover.
Osteoporosis International, 16, 417-423.

99

Javaid, M. K., & Holt, R. I. (2008). Understanding osteoporosis. Journal of
Psychopharmacology, 22, 38-45.
Kanis, J. A., Johansson, H., Johnell, O., Oden, A., De Laet, C., Eisman, J. A., et al.
(2005). Alcohol intake as a risk factor for fracture. Osteoporosis International,
16, 737-742.
Kasukawa Y, Miyakoshi N, S., Mohan (2004). The anabolic effects of GH/IGF system on
bone. Current Pharmaceutical Design, 10, 2577-2592.
Kerstetter, J. E., O'Brien, K. O., Insogna, K. L. (2003). Low protein intake: the impact on
calcium and bone homeostasis in humans. Journal ofNutrition, 133, 855S-861S.
Komine, M., Kukita, A., Kukita, T., Ogata, Y., Hotokebuchi, T., Kohashi, O. (2001).
Tumor necrosis factor-alpha cooperates with receptor activator of nuclear factor
kappaB ligand in generation of osteoclasts in stromal cell-depleted rat bone
marrow cell culture. Bone, 28, 474-483.
Kris-Etherton, P. M., Hecker, K. D., Bonanome, A., Coval, S. M., Binkoski, A. E.,
Hilpert, K. F., et al. (2002). Bioactive compounds in foods: their role in the
prevention of cardiovascular disease and cancer. American Journal ofMedicine,
773, 71S-88S.
Kruger, M., & Scholium, L.M. (2005). Is docosahexaenioc acid more effective than
eicosapentaenoic acid for increasing calcium bioavailability? Prostaglandins
Leukotrienes Essential Fatty Acids, 77, 327-334.
Kruger, M. C., Coetzer, H., de Winter, R., Gericke, G.,van Papendorp, D. H. (1998).
Calcium, gamma-linolenic acid and eicosapentaenoic acid supplementation in
senile osteoporosis. Aging (Milano), 10, 385-394.
100

Kwan, T.S., Padrines, M, Theoleyre, S., Heymann, D., Fortun, Y. (2004). IL-6, RANKL,
TNF-alpha/IL-1: Interrelations in bone resorption pathophysiology. Cytokine &
Growth Factor Reviews, 15, 49-60.
Laboratory, USD A Nutrient Data (2008), from
<http ://www.nal .usda. gov/fnic/foodcomp>
Lark, M. W., & James, I. E. (2002). Novel bone antiresorptive approaches. Current
Opinion in Pharmacology, 2, 330-337.
Laroche, M. (2008). Treatment of osteoporosis: all the questions we still cannot answer.
American Journal ofMedicine, 121, 744-747.
Liu, D., Veit, H. P., Denbow, D. M. (2004). Effects of long-term dietary lipids on mature
bone mineral content, collagen, crosslinks, and prostaglandin E2 production in
Japanese quail. Poultry Science, 83, 1876-1883.
Love, C. (2003). Dietary needs for bone health and the prevention of osteoporosis. British
Journal ofNursing, 12, 12-21.
Macdonald, H. M., New, S. A., Golden, M. H., Campbell, M. K., Reid, D. M. (2004).
Nutritional associations with bone loss during the menopausal transition: evidence
of a beneficial effect of calcium, alcohol, and fruit and vegetable nutrients and of
a detrimental effect of fatty acids. American Journal of Clinical Nutrition, 79,
155-165.
Malyszko, J., Wolczynski, S., Zbroch, E., Brzosko, S., Mysliwiec, M. (2002). Insulin-like
growth factor system components in relation to erythropoietin therapy and bone
metabolism in dialyzed patients and kidney transplant recipients. Nephron, 90,
282-289.
101

Mollard, R. C., Gillam, M. E., Wood, T. M., Taylor, C. G., Weller, H. A. (2005). (n-3)
fatty acids reduce the release of prostaglandin E2 from bone but do not affect
bone mass in obese (fa/fa) and lean Zucker rats. Journal ofNutrition, 135, 499504.

Mollard, R. C., & Weiler, H. A. (2008). Bone resorption varies as a function of time of
day and quantity of dietary long chain polyunsaturated fatty acids. Journal of
Nutritional Biochemistry, 19, 482-488.
Paschos, G. K., Magkos, F., Panagiotakos, D. B., Votteas, V., Zampelas, A. (2007).
Dietary supplementation with flaxseed oil lowers blood pressure in dyslipidaemic
patients. European Journal of Clinical Nutrition, 61, 1201-1206.
Pi, Y. Z., Wu, X. P., Liu, S. P., Luo, X. H., Cao, X. Z., Xie, H., et al. (2006). Age-related
changes in bone biochemical markers and their relationship with bone mineral
density in normal Chinese women. Journal ofBone Mineral Metabolism, 24, 380385.
Poulsen, R. C., Firth, E. C., Rogers, C. W., Moughan, P. J., Kruger, M. C. (2007).
Specific effects of gamma-linolenic, eicosapentaenoic, and docosahexaenoic ethyl
esters on bone post-ovariectomy in rats. Calcified Tissue International, 81, 459471.
Poulsen, R. C., & Kruger, M. C. (2006). Detrimental effect of eicosapentaenoic acid
supplementation on bone following ovariectomy in rats. Prostaglandins
Leukotrienes Essential Fatty Acids, 75, 419-427.

102

Poulsen, R. C., Moughan, P. J., Kruger, M. C. (2007). Long-chain polyunsaturated fatty
acids and the regulation of bone metabolism. Experimental Biology and Medicine,
232, 1275-1288.
Ragab, A. A., Nalepka, J. L., Bi, Y., Greenfield, E. M. (2002). Cytokines synergistically
induce osteoclast differentiation: support by immortalized or normal calvarial
cells. American Journal ofPhysiology- Cell Physiology, 283, C679-687.
Rajaram, S., Haddad, E. H., Mejia, A., Sabate, J. (2009). Walnuts and fatty fish influence
different serum lipid fractions in normal to mildly hyperlipidemic individuals: a
randomized controlled study. American Journal of Clinical Nutrition, 89, 1657S1663S.
Rizzoli, R. (2008). Nutrition: its role in bone health. Best Practice & Research. Clinical
Endocrinology & Metabolism, 22, 813-829.
Ros, E., Nunez, I., Perez-Heras, A., Serra, M., Gilabert, R., Casals, E., et al. (2004). A
walnut diet improves endothelial function in hypercholesterolemic subjects: a
randomized crossover trial. Circulation, 109, 1609-1614.
Rosen, H. N., Moses, A. C., Garber, J., Iloputaife, I. D., Ross, D. S., Lee, S. L., et al.
(2000). Serum CTX: a new marker of bone resorption that shows treatment effect
more often than other markers because of low coefficient of variability and large
changes with bisphosphonate therapy. Calcified Tissue International, 66, 100103.

Sabate, J., Cordero-Macintyre, Z., Siapco, G., Torabian, S., Haddad, E. (2005). Does
regular walnut consumption lead to weight gain? British Journal ofNutrition, 94,
859-864.
103

Sabate', J., Fraser, G. E., Burke, K., Knutsen, S. F., Bennett, H., Lindsted, K. D. (1993).
Effects of walnuts on serum lipid levels and blood pressure in normal men. New
England Journal ofMedicine, 328, 603-607.
Sabate', J., Wien, M, Oda, K, Rajaram, S., Haddad, E. (2009). Effect on red blood cell
membrane fatty acids of diets enriched with different sources of n-3 fatty acids in
healthy adults. Federation ofAmerican Societies for Experimental Biology
Journal, 23, 543.545.
Sahni, S., Hannan, M. T., Gagnon, D., Blumberg, J., Guppies, L. A., Kiel, D. P., et al.
(2008). High vitamin C intake is associated with lower 4-year bone loss in elderly
men. Journal ofNutrition, 138, 1931-1938.
Sakaguchi, K., Morita, I., Murota, S. (1994). Eicosapentaenoic acid inhibits bone loss due
to ovariectomy in rats. Prostaglandins Leukotrienes Essential Fatty Acids, 50, 8184.
Salari, P., Rezaie, A., Larijani, B., Abdollahi, M. (2008). A systematic review of the
impact of n-3 fatty acids in bone health and osteoporosis. Medical Science
Monitor, 14, RA37-44.
Saldanha, L. G., Salem, N., Jr., Brenna, J. T. (2009). Workshop on DHA as a required
nutrient: Overview. Prostaglandins Leukotrienes Essential Fatty Acids, [epub
ahead of print].
Sambrook, P. N., Chen, C. J., March, L., Cameron, I. D., Gumming, R. G., Lord, S. R., et
al. (2006). High bone turnover is an independent predictor of mortality in the frail
elderly. Journal ofBone Mineral Research, 21, 549-555.

104

Sanders, T. A. (2009). DHA status of vegetarians. Prostaglandins Leukotrienes Essential
Fatty Acids, [epub ahead of print].
Services, US Department of Agriculture-US Department of Health and Human (2005).
Report of the Dietary Guidelines Advisory Committee Retrieved September 2007,
from <http://www. health.gov/DietaryGuidelines>
Services, US Department of Health and Human (Ed.). (2004). Bone Health and
Osteoporosis: A Report of the Surgeon General. Rockville, MD: US Department
of Health and Human Services, Office of the Surgeon General.
Shen, C. L., Yeh, J. K., Rasty, J., Li, Y., Watkins, B. A. (2006). Protective effect of
dietary long-chain n-3 polyunsaturated fatty acids on bone loss in gonad-intact
middle-aged male rats. British Journal ofNutrition, 95, 462-468.
Shen, C. L., Yeh, J. K., Rasty, J., Li, Y., Watkins, B. A. (2006). Protective effect of
dietary long-chain n-3 polyunsaturated fatty acids on bone loss in gonad-intact
middle-aged male rats. British Journal ofNutrition, 95, 462-468.
Simopoulos, A. P. (1999). Essential fatty acids in health and chronic disease. American
Journal of Clinical Nutrition, 70, 560S-569S.
Sodergren, E., Gustafsson, I. B., Basu, S., Nourooz-Zadeh, J., Nalsen, C., Turpeinen, A.,
et al. (2001). A diet containing rapeseed oil-based fats does not increase lipid
peroxidation in humans when compared to a diet rich in saturated fatty acids.
European Journal of Clinical Nutrition, 55, 922-931.
Sukenik, A., Takahashi, H., Mokady, S. (1994). Dietary lipids from marine unicellular
algae enhance the amount of liver and blood omega-3 fatty acids in rats. Annals of
Nutrition Metabolism, 38, 85-96.
105

Sun, D., Krishnan, A., Zaman, K., Lawrence, R., Bhattacharya, A., Fernandes, G. (2003).
Dietary n-3 fatty acids decrease osteoclastogenesis and loss of bone mass in
ovariectomized mice.

ofBone Mineral Research, 18, 1206-1216.

Syversen, U., Nordsletten, L., Falch, J. A., Madsen, J. E., Nilsen, O. G., Waldum, H. L.
(1999). Effect of lifelong nicotine inhalation on bone mass and mechanical
properties in female rat femurs. Calcified Tissue International, 65, 246-249.
Szulc, P., & Delmas, P. D. (2001). Biochemical markers of bone turnover in men.
Calcified Tissue International, 69, 229-234.
Tanaka, Y., Nakayamada, S., Okada, Y. (2005). Osteoblasts and osteoclasts in bone
remodeling and inflammation. Current Drug Targets Inflammation Allergy, 4,
325-328.
Thompson, L.U. (Ed.). (2003). Flaxseed in Human Nutrition (2nd ed.). Champaign, IL:
AOCS Press.
Toussirot, E., Nguyen, N. U., Dumoulin, G., Regnard, J., Wendling, D. (1998). Insulin
like growth factor-I and insulin-like growth factor binding protein-3 serum levels
in ankylosing spondylitis. British Journal ofRheumatology, 37, 1172-1176.
Tucker, K. L. (2003). Dietary intake and bone status with aging. Current Pharmacology
Design, 9, 2687-2704.
Van Papendrop, D. H., Coetzer, H., Kruger, M.G. (1995). Biochemical profile of
osteoporotic patients on essential fatty acids supplementation. Nutrition Research,
15, 325-334.
van Staa, T. P., Leufkens, H. G., Cooper, C. (2002). The epidemiology of corticosteroidinduced osteoporosis: a meta-analysis. Osteoporosis International, 13, 777-787.
106

Vega, D., Maalouf, N. M., Sakhaee, K. (2007). CLINICAL Review #: the role of receptor
activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin:
clinical implications. Journal of Clinical Endocrinology & Metabolism, 92, 45144521.
Watkins, B. A., Li, Y., Allen, K. G., Hoffmann, W. E., Seifert, M. F. (2000). Dietary
ratio of (n-6)/(n-3) polyunsaturated fatty acids alters the fatty acid composition of
bone compartments and biomarkers of bone formation in rats. Journal of
Nutrition, 130, 2274-2284.
Watkins, B. A., Li, Y., Lippman, H. E., Feng, S. (2003). Modulatory effect of omega-3
polyunsaturated fatty acids on osteoblast function and bone metabolism.
Prostaglandins Leukotrienes Essential Fatty Acids, 68, 387-398.
Watkins, B. A., Li, Y., Lippman, H. E., Seifert, M. F. (2001). Omega-3 polyunsaturated
fatty acids and skeletal health. Experimental Biology Medicine, 226, 485-497.
Watkins, B. A., Li, Y., Seifert, M. F. (2006). Dietary ratio of n-6/n-3 PUFAs and
docosahexaenoic acid: actions on bone mineral and serum biomarkers in
ovariectomized rats. Journal ofNutrition & Biochemistry, 17, 282-289.
Weaver, K. L., Ivester, P., Chilton, J. A., Wilson, M. D., Pandey, P., Chilton, F. H.
(2008). The content of favorable and unfavorable polyunsaturated fatty acids
found in commonly eaten fish. Journal of American Dietetic Association, 108,
1178-1185.

107

Weiler, H. A., Kovacs, H., Nitschmann, E., Bankovic-Calic, N., Aukema, H., Ogbom, M.
(2007). Feeding flaxseed oil but not secoisolariciresinol diglucoside results in
higher bone mass in healthy rats and rats with kidney disease. Prostaglandins
Leukotrienes Essential Fatty Acids, 76, 269-275.
Weiss, L. A., Barrett-Connor, E., von Muhlen, D. (2005). Ratio of n-6 to n-3 fatty acids
and bone mineral density in older adults: the Rancho Bernardo Study. American
Journal of Clinical Nutrition, 81, 934-938.
Zalloua, P. A., Hsu, Y. H., Terwedow, H., Zang, T., Wu, D., Tang, G., et al. (2007).
Impact of seafood and fruit consumption on bone mineral density. Maturitas, 56,
1-11.
Zambon, D., Sabate, J., Munoz, S., Campero, B., Casals, E., Merlos, M., et al. (2000).
Substituting walnuts for monounsaturated fat improves the serum lipid profile of
hypercholesterolemic men and women. A randomized crossover trial. Annals of
Internal Medicine, 132, 538-546.

108

APPENDIX A: IRB APPROVAL

ip

INSTITUTIONAL REVIEW BOARD
Initial Approval Notice - Expedited Review

IRB# 58239

OFFICE OF SPONSORED RESEARCH • 11183 Anderson Street - Lome IMa. CA 52350

/90S555a-<531fw>c#;'fS09;55W)J3J/to; .

To:

Rajaram, Sujatha

Department:

Nutrition

Protocol:

Effect of dietary n-3 polyunsaturated fat from plant and marine sources on markers
of bone maintenance

This study was review and approved administratively on behalf of the IRB. This decision includes the
following determinations:
Risk to research subjects:
Approval period begins
Stipulations of approval:

Minimal
11-Sep-2008 and ends 10-Sep-2009
Waiver of Informed consent document.

Consent Form
Unless IRB has given a specific waiver of informed consent (as documented in the approval stipulations
above) the IRB-approved and stamped consent form accompanies this letter. This now becomes the official
master consent form for making copies to provide to study participants.

Adverse Events / Protocol Changes
The IRB should be notified in writing of any modifications to the approved research protocol. Adverse
effects must be reported to the IRB in accordance with institutional policy. If sponsor or contractual adverse
event reporting requirements differ from requirements for reporting to IRB, ali reporting requirements must
still be met.

Protocol Review
Your protocol is tentatively scheduled for review and renewal at least two weeks prior to the approval enddate indicated above. To assure uninterrupted approval of this project, you will be sent a report form to
request renewal by completing and timely returning, to Office of Sponsored Research. Anticipate the
approval expiration so your study does not lapse; contact IRB for assistance if necessary. In addition to
reporting the requested renewal status information, you may also use the form to close the study at that
time, if applicable.

Records
All records relating to this project, including signed consent forms, must be kept on file for three years
following completion of the study.Please note the Pi’s name and the IRB number assigned to this IRB
protocol (as indicated above) on any future communications with the IRB. Direct all
communications to the IRB c/o the Office of Sponsored Research. Thank you for your cooperation in
LLU’s shared responsibility for the ethical use of human subjects in research.

Signature of IRB Chair/Designee:.
loma Linda University Adventist Health Sciences Center' holds FedaraWdo Assurance (FWA) No. &*47 with the US. Oltlce lor Human Research Protections, and
the IRB refl's(ration no. is IORG226. This Assurance applies to the following mstortionj: Lome Linda University, Lama Linda University Medical Center (including
Loma Unda University Children's Hospital, LLU Commonty Med'cai Center), Loma Unda University Behavioral MecScine, and affilated medcaJ practices groups.

109

APPENDIX B: INFORMED CONSENT

cQ^ia cQnda ^University
School of Public Health

The Effect of Walnuts and Fish on Blood Lipids in Healthy Adults

Loma Linda, California 92350
(909) 558-4546
FAX: (909) 558-4087

Informed Consent
Purpose and Procedures
You are invited to participate in a research study comparing the effect on human blood lipids of daily
consumption of walnuts and twice a week consumption of fish. Your participation will require the
following commitments over a 14 week period:
You will have two interviews with the investigators and a screening blood draw to determine your
eligibility for the study. Throughout the fourteen weeks of the study afi your meals will be provided by
the researchers and you will eat nothing outside the diet provided. You will be required to go to the
Research Kitchen of the University twice a day (breakfast and supper) Sunday through Friday (6 days a
week). Your daily lunch meals, Friday dinner and all Saturday meals will be provided to you to go. For
the first week you will consume a typical American diet that includes all the food groups but contains no
nuts or fish. The next 13 weeks (one week off for Memorial Day) will consist of three different diets of
four weeks each, one a low fat diet, the second a walnut-rich diet and the third a fish diet. The nuts will
be eaten alone, mixed in salads and cereals or cooked in entrees. Fish will be prepared and served as
entrees. Your weight will be recorded every day during the first two weeks and twice a week thereafter.
A total of 8 blood drawings, requiring 6 tablespoons of blood each, will be performed after fasting for a
minimum of 12 hours: two at the beginning of the study and two at the end of each of the three diet
periods. A 12 hour overnight urine collection will be needed at the end of each diet period for a total of 3
urine collections.
Risks
There is a small possibility of developing an allergy to walnuts or fish. Possible complications of blood
drawing are slight pain and minor bleeding/bruising at the point of needle insertion. Apart from the blood
tests, none of the other procedures are associated with risk or significant discomfort. The committee at
Loma Linda University that reviews human studies (Institutional Review Board) has determined that
participating in this study exposes you to minimal risk.
Benefits
The potential benefit of participating in this study is to learn more about your cardiovascular health from
the results of the blood tests and diet questionnaires. These will be performed free of charge. The
potential benefits to health care professionals are increased knowledge of the relationship of fatty acids
from walnuts and fish to cardiovascular risk factors.

I have read this informed consent.
Date
___ _ Initials
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Costs/Compensation
Since completion of the entire experiment is important to the success of the whole study, you will receive
a total of S400 at the end of the 14 weeks of participation. You will receive only $50 if you withdraw
after 5 weeks but before completion of the study. There is no charge to you for any of the meals provided
or for any portion of this study, Despite the above, you may withdraw unconditionally at any time.
Confidentiality
The information obtained in this study is confidential, and your name and identity will not be disclosed in
any published document.
Research Related Iniurv
In the unlikely event of physical injury, you may contact the principal investigators, Dr. Ella Haddad or
Dr. Sujatha Rajaram at 909-558-4598.
Third Party Contact
If you wish to contact an impartial third party not associated with this study regarding any complaint you
may have about the study, you may contact Jean Fankhanel, Patient Relations, Loma Linda University
Medical Center, Loma Linda, CA 92350, phone 909-558-4647 for information and assistance.
Informed Consent Statement
I have read the contents of this consent form and have listened to the verbal explanation given by the
investigators. I understand the commitment required, also the potential risks and benefits. My questions
concerning this study have been answered to my satisfaction. I hereby give voluntary consent to
participate in this study. I may call Dr. Ella Haddad or Dr. Sujatha Rajaram at 909-558-4598 if I have
additional questions or concerns. I have been given a copy of this consent form.

Signature of Subject

Date

Witness

I HAVE REVIEWED THE CONTENTS OF THIS FORM WITH THE PERSON SIGNING ABOVE. I
HAVE EXPLAINED POTENTIAL RISK AND BENEFITS OF THE STUDY.

-mm

Date
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%

(Page 2 of 2)

111

INSTITUTIONAL REVIEW BOARD
/,/ .
APPROVEDVOID AFTER Ol/2y/^ocL>
#S50Q/ CHAIR

a

APPENDIX C: POOLED ANALYSES FROM THE FISH-WALNUT AND
OMEGA-3 STUDY ON THE ASSOCIATION BETWEEN BONE MARKERS AND
INDIVIDUAL N-3 PUFAS
MARKER

LIPID

EFFECT

CTX

LA

CTX

CTX

CTX

ALA

EPA

DHA

NumDF

DenDF

FValue

ProbF

LA

1

130

0.08

0.7839

LA GROUP

1

130

0.01

0.9054

LA*LA GROUP

1

130

0.00

0.9957

Study

1

130

0.09

0.7609

PER

3

130

6.60

0.0003

Study*PER

3

130

3.63

0.0147

ALA

1

134

1.09

0.2977

ALA GROUP

1

134

0.02

0.9002

ALA*ALA GRO
UP

1

134

0.65

0.4208

Study

1

134

0.42

0.5195

PER

3

134

7.57

0.0001

Study* PER

3

134

3.90

0.0104

EPA

1

134

0.03

0.8644

EPA GROUP

1

134

1.79

0.1835

EPA*EPA GRO
UP

1

134

0.01

0.9131

Study

1

134

0.02

0.8967

PER

3

134

6.84

0.0003

Study*PER

3

134

4.08

0.0083

DHA

1

137

1.25

0.2646

DHA GROUP

1

137

0.02

0.8890

DHA*DHA GR
OUP

1

137

1.02

0.3144

Study

1

137

0.04

0.8395

PER

3

137

7.66

<.0001

Study*PER

3

137

4.52

0.0047
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MARKER

LIPID

EFFECT

P1NP

LA

P1NP

P1NP

P1NP

oc

ALA

EPA

DHA

LA

NumDF

DenDF

FValue

ProbF

LA

1

130

2.44

0.1211

LA GROUP

1

130

1.13

0.2899

LA*LA GROUP

1

130

2.17

0.1432

Study

1

130

0.73

0.3930

PER

3

130

2.56

0.0579

Study*PER

3

130

5.19

0.0020

ALA

1

134

1.79

0.1832

ALA GROUP

1

134

0.36

0.5479

ALA*ALA GRO
UP

1

134

1.87

0.1734

Study

1

134

0.14

0.7040

PER

3

134

2.61

0.0544

Study*PER

3

134

5.01

0.0025

EPA

1

134

0.00

0.9999

EPA GROUP

1

134

0.04

0.8371

EPA*EPA GRO
UP

1

134

0.32

0.5696

Study

1

134

0.30

0.5852

PER

3

134

2.83

0.0409

Study*PER

3

134

5.08

0.0023

DHA

1

137

0.08

0.7767

DHA GROUP

1

137

2.31

0.1310

DHA*DHA GR
OUP

1

137

2.21

0.1394

Study

1

137

0.67

0.4146

PER

3

137

3.28

0.0229

Study*PER

3

137

5.30

0.0017

LA

1

130

0.33

0.5666

LA GROUP

1

130

0.05

0.8183

LA*LA GROUP

1

130

0.07

0.7978

Study

1

130

2.46

0.1191

PER

3

130

1.28

0.2836
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MARKER LIPID

oc

OC

oc

ALA

EPA

DHA

NumDF

DenDF

FValue

ProbF

Study*PER

3

130

6.57

0.0004

ALA

1

134

7.14

0.0085

ALA GROUP

1

134

0.25

0.6199

ALA*ALA GRO
UP

1

134

3.41

0.0671

Study

1

134

4.53

0.0352

PER

3

134

0.74

0.5319

Study*PER

3

134

6.83

0.0003

EPA

1

134

0.02

0.8848

EPA GROUP

1

134

0.06

0.8055

EPA*EPA GRO
UP

1

134

0.03

0.8557

Study

1

134

1.57

0.2121

PER

3

134

1.01

0.3927

Study*PER

3

134

7.29

0.0001

DHA

1

137

1.63

0.2036

DHA GROUP

1

137

0.80

0.3729

DHA*DHA GR
OUP

1

137

0.24

0.6227

Study

1

137

1.17

0.2805

PER

3

137

1.97

0.1206

Study*PER

3

137

7.67

<.0001

EFFECT
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